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ABSTRACT 
Estrogens, acting via estrogen receptor  (ER), stimulate the proliferation and 
metastatic potential of breast cancers, and likely some ovarian, endometrial, and 
cervical cancers. Endocrine therapy targeting these cancers often leads to development 
of resistance. Ovarian cancers do not respond to endocrine therapy. The presence of 
ER in many resistant tumors suggested the existence of additional modes of ER 
action that could be targeted with small molecule biomodulators.  
To identify new small molecule inhibitors that target the estrogen-ER axis in 
cancer cells resistant to current therapies, we developed and implemented an unbiased 
pathway-directed screen of ~150,000 small molecules. Using screening and functional 
validation, I identified BHPI, a potent non-competitive small molecule ER inhibitor. At 
100 nM, BHPI completely inhibited estrogen-induced proliferation in ER containing 
breast, ovarian and endometrial cancer cells with no effect at 10,000 nM in counterpart 
ER negative cells. BHPI effectively targets cancer cells that no longer depend on 
estrogens for growth, kills drug-resistant breast and ovarian cancer cells, and restores 
paclitaxel sensitivity to multi-drug resistant cancer cells. In a mouse xenograft, BHPI at 
15 mg/kg daily for 10 days induced rapid and substantial regression of 48/52 large 
tumors and was not toxic.  
BHPI’s effectiveness in a broad range of ER-containing breast, ovarian and 
endometrial cancer cells is due to its ability to target the endoplasmic reticulum stress 
sensor pathway, the unfolded protein response (UPR). In ER positive cancer cells, 
BHPI opens the endoplasmic reticulum IP3R calcium channel, triggering efflux of 
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calcium into the cytosol, strongly activating all three arms of the UPR. BHPI activates 
the PERK arm of the UPR, which leads to phosphorylation of eukaryotic initiation factor 
2 (eIF2), and potent inhibition of protein synthesis. To restore endoplasmic reticulum 
calcium, calcium-ATPase pumps are activated, but the calcium rapidly leaks back out 
through the open IP3R channel, creating an ATP-depleting futile cycle. ATP depletion 
activates the energy sensor, AMPK. The influx of calcium into the cytosol leads to 
phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2), inhibiting the 
elongation step of protein synthesis. Inhibiting protein synthesis at a second site 
prevents synthesis of chaperones and other proteins that normally resolve UPR stress. 
BHPI kills ER positive cancer cells by triggering a lethal cascade encompassing 
sustained activation of the UPR, persistent inhibition of protein synthesis, and depletion 
of ATP stores. 
BHPI selectively targets the UPR in ER positive cancer cells by distorting a 
previously unknown ability of estrogen-ER to stimulate a weak and transient UPR 
activation that protects cancer cells from subsequent stress. This anticipatory activation 
of the UPR by estrogen-ER is essential for estrogen-ER-induced gene expression 
and cell proliferation, and is a new paradigm by which estrogens promote therapy-
resistance and tumor progression. Bioinformatic analysis of data from ≈1,000 ER 
positive breast tumors shows that estrogen-ER and UPR activity become elevated 
during tumor development and that a UPR gene signature is a powerful new prognostic 
biomarker predictive of resistance to tamoxifen therapy, time to relapse, and overall 
survival.  
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We employed a novel approach to identifying new pathways and cancer 
biomarkers in which unbiased high throughput screening is used to “interrogate the 
cell”. For a well-studied protein, such as ER, it was unclear whether this approach 
could identify new pathways and biomarkers and promising new drug candidates. 
These studies demonstrate the potential of small molecules identified through targeted 
cell-based screening to reveal and validate new pathways of action, therapeutic drug 
targets, and small molecule therapeutic candidates; even in a system as intensively 
studied as ER positive breast cancer. 
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CHAPTER 1 
 
INTRODUCTION 
Estrogen Receptors  
 Estrogens play a fundamental role in the development of the female reproductive 
system, and regulate the growth and function of tissues such as the breast, uterus, and 
ovaries. The most potent estrogen, 17β-estradiol (E2), is present in the circulation of 
females from the onset of puberty to menopause, and can promote abnormal cell 
growth and eventually lead to the development of cancer. The effects of estrogens are 
largely mediated through binding to estrogen receptor (ER), which belongs to the 
superfamily of steroid nuclear receptors. 
There are two major subtypes of estrogen receptor, ER and ERβ. ER is found 
on chromosome 6q and encodes a 595 amino acid protein, while ERβ is found on 
chromosome 14q and encodes a 530 amino acid protein. ER isoforms have distinct 
tissue expression patterns. ER is expressed widely throughout the body with 
significant expression in the uterus, ovary (theca cells), breast, bone, and regions of the 
brain. ERβ is also expressed widely throughout the body, but is expressed in particularly 
high amounts in the prostate, ovary (granulosa), colon, lung, bone marrow, and testis, 
and in relatively low amounts in the uterus (1). 
Estrogen receptors are composed of six functional regions or domains. The N-
terminal (A/B) domain contains a ligand-independent and functionally minor activating 
function (AF)-1 domain (2, 3). The DNA binding domain (DBD) or C region, consists of 
66-amino acid motif that forms two zinc fingers that interact with DNA. The hinge 
domain (D), contains the nuclear localization signal and interacts with heat shock 
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proteins. The E region, or ligand binding domain (LBD), interacts with E2, and overlaps 
with the ligand-dependent, major transcriptional activation function (AF)-2 domain. The 
C-terminal region, or F domain, inhibits dimerization of the receptor until it is bound by 
ligand.  
 
The Genomic Actions of Estrogen Receptor  (ER) 
The best characterized action of estrogens, acting through ER, is the regulation 
of nuclear gene transcription. In the nucleus, unliganded monomeric ER is complexed 
with heat shock proteins (HSPs). When estrogens diffuse into the cell and bind to the 
LBD of the ER-HSP complex, ER dissociates from HSPs. The LBD of ER then 
undergoes a critical conformation change in which helix 12 covers the ligand binding 
pocket of ER. ER homodimerizes with another ER molecule and binds to specific 
DNA response elements, or estrogen response elements (EREs). Once bound to EREs, 
the AF-2 domain of ER, which contains an LXXLL-like motif, mediates the recruitment 
and docking of an array of coactivators including the p160 superfamily (SRC-1, SRC-
2/GRIP1/TIF2, and SRC-3/AIB1) (4-6). The C-terminal domain of p160 coactivators 
then recruits additional coactivators including the p300/CBP histone acetyltransferase, 
CARM1 methyltransferase, and ubiquitin ligases, UbC and UbL. These additional 
coactivators acetylate, methylate, or ubiquitinate specific residues in the multi-protein 
complex that leads to chromatin remodeling and recruitment of RNA polymerase 
(RNAP) to the promoter of ER-regulated genes, resulting in the transcriptional 
activation of ER-target genes. 
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While ER commonly interacts directly with estrogen-response elements (EREs) 
(7-9), ER can also act through a tethering mechanism to indirectly regulate gene 
transcription. E2-ER can bind to ERE half sites and be brought to DNA through 
interactions with activator protein 1 (AP1), Sp1, and NFB transcription factors bound at 
SP1 and AP-1 sites (10-15). Through these mechanisms estrogen receptor modulates 
transcription of hundreds of genes, leading to the numerous physiological responses of 
estrogens. 
 
Non-Genomic Pathways of Estrogen Receptor Action  
While estrogens promote a slow transcriptional response, they also trigger rapid, 
non-genomic signaling cascades that contribute to estrogen-stimulated proliferation, 
survival, and migration. These events occur within seconds to minutes and can be 
activated by estrogen receptor lacking a nuclear localization signal or by ER targeted to 
the plasma membrane, suggesting that these non-genomic effects of estrogen are 
mediated through additional receptors for estrogens that are not localized to the 
nucleus. A fraction of the ER and ERβ in many cells localizes to the plasma 
membrane and to cytoplasmic organelles including the mitochondria and endoplasmic 
reticulum (16, 17). While there is general agreement that some sort of estrogen-binding 
receptor is present on the plasma membrane, there remains considerable disagreement 
as to the nature of the receptor. The most popular candidates are some forms of the 
nuclear receptors ER and ERβ that allow membrane localization, and GRP30 or some 
other type of membrane receptor. 
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Rapid estrogen signaling from the plasma membrane was first discovered many 
decades ago (18, 19), and it is suggested that 5-10% of cellular ER is localized to the 
plasma membrane in most cells. Numerous reports suggest that ER can associate 
with the plasma membrane through posttranslational modifications (20). ER is 
trafficked to the plasma membrane through interactions with the protein, caveolin-1 (21), 
which assists transport of ER to caveolae rafts in the membrane. Studies have shown 
that cysteine 447 in the E domain of ER functions as part of a larger palmitoylation 
motif, which allows ER to interact with caveolin-1 (20, 22).  Membrane-localized ER 
has been shown to associate with and activate several G proteins, such as G and Gβy 
proteins (23, 24), resulting in the generation of cAMP and calcium, and the activation of 
numerous kinases (Src, PI3K, ERK, and AKT). While the precise functions of plasma 
membrane localized ER remains elusive, these effects of plasma membrane localized 
ER may modulate the transcriptional effects of nuclear ER (25).  
Numerous studies have also investigated whether the non-genomic effects of E2 
are mediated through the orphan GPCR, known as GPR30. GPR30 is overexpressed in 
ER+ breast cancer cell compared to ER- cells (26). In addition, GPR30 is expressed 
in a number of tissues with the highest levels of expression in breast, placenta, and 
heart tissue (26). It is also expressed in the endometrium, ovary, and vascular 
endothelium. Nanomolar amounts of E2, tamoxifen, and fulvestrant all bind to GPR30 
(27). However, ER ligands like DES, have minimal binding affinity for GPR30. While 
GPR30 may contribute to the nongenomic effects of estrogens, considerable 
controversy exists concerning the localization and functional role of the receptor in 
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estrogen signaling. While non-genomic signaling by ER likely helps to facilitate the 
genomic actions of ER, it alone cannot stimulate growth (28), suggesting the estrogen-
dependent proliferation in the breast requires nuclear genomic signaling. Furthermore, 
four different GPR30 knockout mice have been created, and each has shown minimal 
phenotypic alterations with no disruption of normal development of mammary or 
reproductive tissue (29). In contrast, ER knockout mice produce profound effects on 
development of the uterus, mammary gland, and ovary (30). 
Several truncated ER and ERβ proteins have also been reported to play a role 
in the non-genomic actions of estrogens (31), and another putative estrogen receptor 
has been reported in the central nervous system. In the hypothalamus, estradiol is 
believed to bind to a GPCR, which is unrelated to GPR30 (32). Other studies have 
shown that a diphenylacrylamide ligand, known as STX, displayed no binding affinity for 
ER or ERβ, but mimicked the effects of E2 in animal studies and may play a role in 
energy homeostasis (33). Thus, ongoing work continues to identify additional estrogen 
receptors, which may play important roles in promoting the actions of estrogens.  
The most notable nongenomic effects of estrogen-ER include rapid activation of 
phosphatidylinositol-3-kinase leading to the activation of Akt (34-36), activation of 
p42/p44 mitogen-activated protein kinases (MAPKs) (37), and increases in intracellular 
calcium through activation of PKA and PLC (38-40). Activation of these pathways and 
others helps to support the genomic actions of ER, and the integration of these 
molecular events is required to obtain the complete cellular response to estrogens. 
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Endocrine Therapy in Breast Cancer Treatment 
Sustained exposure to estrogens is a well-established cause of breast cancer 
(41, 42), underpinning the development of targeted therapies that inhibit the actions of 
estrogens (43-45). At diagnosis, more than two-thirds of breast cancers are classified as 
ER positive (46), and interference with estrogen action has remained a mainstay in 
breast cancer treatment for many decades (43, 45, 47). Endocrine therapies fall into two 
broad categories: (i) tamoxifen, fulvestrant/Faslodex/ICI 182,780 and other 
antiestrogens that compete with estrogens for binding to ER and (ii) aromatase 
inhibitors that inhibit the production of estrogen. 
The functional significance of ER in breast cancer has made it the foremost 
target for the development of anti-hormonal therapies aimed at preventing and treating 
breast cancer. Antiestrogens fall into two broad categories. The first class is 
represented by selective estrogen receptor modulators (SERMs) and includes 
tamoxifen, raloxifene, and tornofine. Theses SERMs inhibit AF-2 activation and thereby 
prevent ER activity, but do not prevent activation of the AF-1 domain of ER. Since 
ER activity in the breast epithelium is largely due to AF-2 activation, tamoxifen and 
other SERMs function as antagonists in breast cells. In other tissues, such as the 
uterus, AF-1 activity is more significant and some SERMs function as partial agonist. 
Thus, SERMS function as mixed agonists/antagonists. Binding of SERMs, such as 4-
OHT and raloxifene, induces a distinct conformational change in ER that prevents 
coactivator recruitment and enhances recruitment of corepressor molecules. At the 
molecular level, the side-chains of antiestrogens protrude from the ligand-binding 
pocket of ER, which prevents helix-12 from sealing the ligand-binding-pocket, which 
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prevents recruitment of coactivators to ER (48, 49). In large-scale randomized clinical 
trials, initiating tamoxifen therapy for 5-years immediately following surgery in patients 
diagnosed with early-stage ER+ breast cancer reduced breast cancer mortality by 28% 
(50).  
The second class of antiestrogens are the ‘pure’ antagonists, which includes ICI 
182,780 (Fulvestrant/Faslodex). Pure antagonists prevent activation of the AF-1 and 
AF-2 domains of ER. At the molecular level, the long hydrophobic side-chain of ICI 
182,780 (ICI) prevents the binding of helix-12 to the surface of the ligand-binding 
domain, which prevents ER transcriptional activation. In addition, ICI 182,780 (ICI) 
promotes the rapid destruction of ER in breast cancer cells in cell culture, the mouse 
uterus, and breast tumors in vivo (51-53). While ICI has shown considerable efficacy in 
cell culture at concentrations between 100-1000 nM, the average concentration of ICI in 
patients after 6 months of dosing was only 10 nM (54), demonstrating that it is difficult to 
achieve comparable circulating plasma concentrations of ICI in patients. Even though 
fulvestrant has not proven to be better than SERMs, ICI is not cross-resistant with 
tamoxifen in several athymic models of tamoxifen-stimulated breast and endometrial 
cancer (55-57), and therefore represents an additional treatment option for women with 
breast cancer whose disease fails to respond to other therapies.  
As the second arm of endocrine therapy, aromatase inhibitors block the 
synthesis of estrogens, and therefore abolish an endocrine response in ER+ breast 
cancers. Since most cases of breast cancer occur in post-menopausal women, ovarian 
synthesis of estrogens has ceased. However, studies in post-menopausal women have 
shown that estrogen concentrations within breast tumors can be 20-fold higher than the 
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blood plasma concentration of estrogen, suggesting that non-ovarian sources of E2 play 
an important role in driving ER+ breast cancers. Local estrogen synthesis is dependent 
on the p450 enzyme, aromatase, which converts androgens (testosterone and 
androstenedione) into estrogens (estradiol and estrone). Thus, blocking estrogen 
synthesis using aromatase inhibitors (AIs) represents an effective way of indirectly 
targeting ER in breast cancer. There are two classes of agents used to prevent the 
CYP19 aromatase enzyme from synthesizing estrogen: competitive inhibitors (letrozole 
or anastrozole) and suicide inhibitors (exemestane). Both experimental and clinical data 
now have confirmed that aromatase inhibitors achieve greater response rates compared 
to tamoxifen (58-60), which may be due to the fact that tamoxifen functions as a partial 
agonist and therefore may limit tamoxifen’s clinical efficacy. 
 
Resistance to Current Endocrine Therapies 
While current endocrine therapies targeting estrogen represent a significant 
advance in breast cancer therapy, many women develop resistance to these therapies. 
Selection and outgrowth of breast cancers resistant to endocrine therapy is common, 
and most deaths due to breast cancer are in patients with ER+ tumors (61). In ER+ 
breast cancer, one-third of women treated with tamoxifen for 5 years will develop 
recurrent disease within 15 years. The development of resistance to tamoxifen and to 
aromatase inhibitors remains a key problem in breast cancer treatment (62). A number 
of mechanisms are involved in the development of resistance to endocrine therapies.  
Numerous studies have suggested that altered expression of ER plays an 
important role in resistance to tamoxifen therapy. Loss of ER expression remains the 
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primary mechanism of de novo or intrinsic resistance to endocrine therapies. While 
some studies have implicated the loss of ER expression as a mechanism of acquired 
resistance, this only occurs in 15-20% of resistant breast cancers, and represents a 
small subset of therapy resistant tumors. In contrast, ER overexpression occurs in the 
majority of breast cancers in postmenopausal women, and gross overexpression of 
ER has been associated with increased recurrence and reduced response to 
tamoxifen therapy. 
Given the complexity of ER transcriptional activation, endocrine resistance is 
often linked to changes in the levels and activity of several proteins involved in forming 
transcriptional complexes with ER. This includes other transcription factors, such as 
activator protein 1 (AP1) and NF-B, which interact with ER and are often associated 
with endocrine resistance. It also includes expression of ER co-activator molecules, 
particularly nuclear receptor co-activator 3 (nCOA3/AIB1/SRC3), which can lead to 
constitutive ER-mediated transcription, and can confer resistance in xenograft models 
and is associated with reduced responsiveness to tamoxifen therapy. The coactivator 
pElp1 is also associated with tamoxifen resistance. pElp1 localizes to the cytosol and 
functions as a scaffolding protein, which allows ER to interact with and activate SRC, 
which in turn leads to activation of MAPKs.  
Accumulating data suggest that growth-factor-receptor signaling pathways might 
be overexpressed in tumors resistant to tamoxifen, suggesting that over time, breast 
cancer cells use alternative intracellular signaling pathways to enhance and activate 
ER signaling. While ER activity has classically been viewed as requiring ligand 
binding, bidirectional cross-talk between ER and growth factor receptor signaling 
10 
 
pathways can stimulate post-translational modifications of ER and stimulate ER 
activation in a ligand-independent fashion (63-65). Increased expression of members of 
the epidermal growth factor receptor (EGFR) family, such as EGFR and ERBB2 
(HER2/neu), and the insulin-like growth factor receptor (IGFR) family, are both linked to 
tamoxifen-resistance (63, 64, 66). Activation of the MAPK/ERK pathway by upstream 
growth factors (ERBB2, EGFR), the AKT/PI3K pathway by IGF growth factors, and 
activation of the p38 MAPK pathway by stress and/or cytokines can all lead to 
phosphorylation of key residues of the AF-1 domain of ER and ligand-independent 
activation of ER (59).  
While estrogen-deprivation therapy might be more effective than tamoxifen in 
delaying resistance, eventually tumors become resistance to aromatase inhibitors. One 
important mechanism allowing tumors to escape suppression by aromatase inhibitors is 
the ER hypersensitivity mechanism, which increases the sensitivity of ER to lower 
circulating levels of E2. In wild-type MCF-7 cells, the cells respond maximally to doses of 
E2 in the range of 10-11 M. However, in MCF-7 cells deprived of estrogens for extended 
periods (LTED cells), the cells adapt and respond maximally to E2 concentrations of 10-
13 (67-70). In addition, there is considerable evidence that signaling cross-talk between 
growth-factor-signaling pathways and ER readily occurs at the time of tumor relapse. 
This can lead to hyperactivation of ER and increased sensitivity of ER to lower levels 
of estrogens, via cross-talk through the MAPK and the IFG/AKT signaling pathways. 
Increased expression of ERBB2/ERBB3, MAPK, and IGFR might therefore activate 
residual and increased levels of ER, similar to cells that have become resistant to 
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tamoxifen (71-74). Thus, ER signaling remains integral to breast cancer therapy, even 
in the context of aromatase inhibitors. 
 
Estrogen Action and Endocrine Therapy in Gynecological Malignancies 
Most epithelial ovarian cancer (EOC) presents at an advanced stage (Stage 3 or 
4). Although 30-70% of these tumors are ER positive (75), most tumors display de 
novo resistance to endocrine therapy (76-78). Tumors are treated with combination 
chemotherapy using taxanes and platinum, but after several cycles of treatment, tumors 
typically recur (79). Therapeutic options for these resistant tumors are poor and 
approximately two-thirds of ovarian cancer patients die within 5 years (80). However, 
the presence of ER in most therapy-resistant gynecologic cancers suggests that there 
may exist additional modes of ER action, which can be targeted with small molecules. 
 
Overview of Thesis  
Here I present a novel approach to breast cancer therapy and to identification of 
new modes of ER action. We used high throughput screening to identify a novel ER 
biomodulator, BHPI; demonstrated that BHPI is a promising new anticancer drug, 
effective in ER containing tumor cells resistant to current therapies; identified 
anticipatory activation of the endoplasmic reticulum stress sensor, the unfolded protein 
response, as the surprising pathway of action of BHPI; showed that BHPI is distorting a 
normal action of ER; and showed that the weak anticipatory activation of the UPR is 
an important initial signal required for subsequent estrogen-ER mediated cell 
proliferation and gene expression. I also show that elevated expression of a UPR gene 
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index is a powerful new prognostic marker in ER positive breast cancer, tightly 
correlated with reduced time to tumor recurrence, tamoxifen resistance and poor 
survival. 
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CHAPTER 2 
EVALUATION OF A LUCIFERASE-BASED REPORTER ASSAY FOR 
INHIBITORS OF ESTROGEN RECEPTOR α ACTION AS A SCREEN 
FOR INHIBITORS OF ESTROGEN-ERα-INDUCED PROLIFERATION OF 
BREAST CANCER CELLS 1 
 
Abstract 
Since estrogens (E2), acting through estrogen receptor  (ER), stimulate 
proliferation of breast cancer cells, ER is an attractive drug target. Because screening 
small molecule inhibitors of cell proliferation is challenging in 384-well format, inhibition 
of luciferase-based reporters is often used as a surrogate end-point. To identify novel 
small molecules inhibitors of E2-ER-stimulated cell proliferation, we established a cell-
based screen for inhibitors of 17-estradiol (E2)-ER induction of an estrogen response 
element ((ERE)3-Luciferase) reporter. 75 “hits” were selected to evaluate the 
effectiveness of the luciferase assay in predicting inhibitors of E2-ER induced 
proliferation of breast cancer cells. Only ~10% of the hits from the luciferase screen 
inhibited estrogen-induced proliferation of ER positive MCF-7 and T47D cells, but not 
control ER negative MDA-MB-231 cells. While a few compounds inhibited E2-ER-
stimulated proliferation in only one of the ER positive cell lines, most compounds either 
                                                          
1 This chapter appeared in its entirety in the Journal of Biomolecular Screening. Andruska N, Mao C, 
Cherian M, Zhang C, Shapiro DJ. (2012) Evaluation of a luciferase-based reporter assay as a screen for 
inhibitors of estrogen-ERalpha-induced proliferation of breast cancer cells. J Biomol Screen. 17(7): 921-
32. This article is reprinted with the permission of the publisher. 
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were toxic and inhibited growth of all the cell lines, or exhibited little or no ability to 
inhibit E2-ER-stimulated cell proliferation. Representative compounds were evaluated 
in more detail and a lead ER inhibitor was identified. HTS using luciferase reporter 
assays represent a viable, but imperfect, way to identify small molecule inhibitors of cell 
proliferation. 
 
Introduction 
High throughput screens based on luciferase reporter assays are widely used to 
evaluate the effects of compounds on a pathway or target of interest (1). Reporter 
assays are often used as surrogate markers for a process such as cell proliferation that 
is more difficult to establish for full 384 or 1536 well HTS. Although there have been 
several studies of off-target effects due to direct interaction of a compound with the 
luciferase protein (2, 3), much less is known about the ability of a simple luciferase 
reporter assay to predict small molecule effects on a complex process, such as cell 
proliferation. Using inhibitors of estrogen receptor  (ER) as a model, we evaluated 
how effectively a primary screen based on inhibition of a luciferase reporter predicted 
the ability of small molecules to selectively inhibit estrogen-ER-dependent growth of 
human breast cancer cells.  
The complex of estrogens, such as 17-estradiol (E2) and ER plays a critical 
role in the growth and metastases of breast cancer. The important role of estrogens in 
breast cancer is illustrated by the widespread therapeutic use of aromatase inhibitors 
that block estrogen production, and the selective estrogen receptor modulators 
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tamoxifen and faslodex/fulvestrant/ICI 182,780 that work by competing with estrogens 
for binding to ER (4). The progressive development of tumors resistant to tamoxifen 
and other ER antagonists (5), and to aromatase inhibitors (6), underscores the 
continued importance of ER as a therapeutic target.  
It is widely accepted that the ability of E2-ER to regulate nuclear gene 
expression plays a key role in the ability of estrogens to stimulate proliferation of ER 
positive breast cancer cells (7, 8). The E2-ER complex regulates gene expression by 
direct binding to DNA sequences termed estrogen response elements (EREs) and 
closely related sequences and by tethering to DNA through other proteins bound at AP1 
and SP1 sites. The E2-ER complex can also act in the cytosol to rapidly activate 
several membrane-associated protein kinase-based signaling pathways. However, rapid 
activation of the pro-growth ERK1/2 signaling pathway by E2-ER complex is not 
sufficient for E2-dependent growth of breast cancer cells (9). 
Recent reports have described assays using growth as a biological end-point 
(10). Although effective in 96-well plates, our assays for E2-ER-stimulated proliferation 
of breast cancer cells did not exhibit sufficient reproducibility and precision for use in 
384-well HTS. We therefore developed a screen using endogenous ER in T47D, 
human breast cancer cells, stably transfected to express a luciferase reporter containing 
3 consensus EREs ((ERE)3-luc) (11). The readout is the ability of small molecules to 
inhibit the E2-ER induction of the (ERE)3-luc reporter. Although E2-ER regulated gene 
expression is essential for E2-ER-dependent cell proliferation, we found that there was 
an imperfect relationship between the inhibitory potency of compounds in the luciferase 
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reporter assay and their potency as selective inhibitors of estrogen-dependent cell 
proliferation. This led us to characterize in some detail the properties of 75 verified hits 
from the reporter assay. ~10% of the verified hits functioned as selective inhibitors of 
E2-ER-stimulated proliferation of breast cancers cells. We identified several causes for 
the failure of most of the hits to function as selective inhibitors. While imperfect 
predictors of selective inhibitory potency in cell proliferation assays, luciferase reporter 
assays nevertheless represent a useful primary screen. 
 
Materials and Methods 
Cell Culture 
Human breast cancer cell lines were maintained in the following culture media. 
MCF-7: phenol red-free minimal essential medium (MEM), supplemented with 5% FBS; 
T47D: MEM, supplemented with 10% FBS; T47D-KBluc: RPMI-1640, supplemented 
with 10% FBS;(12) MDA-MB-231: phenol red-free MEM, supplemented with 10% FBS. 
Prior to experiments, ER(+) cell lines were maintained for at least 3 days in phenol 
red-free charcoal-dextran (CD) treated serum. T47D cells: 4 days in MEM containing 
10% CD-FBS; MCF-7 cells: 4 days in MEM + 5% CD-FBS; T47D-KBluc cells: 3 days in 
RPMI1640 + 10% CD-FBS. 
 
Automated HTS and Manual 384-Well Plate Luciferase Assays 
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HTS luciferase-based assays were carried out by adding test compounds to 
plates using a Matrix PlateMate Plus instrument (ThermoScientific), equipped with a 
384-well pin-transfer apparatus. To reach the desired final concentration for screening 
with limited volume options available using the pin transfer apparatus, 0.1 l of each 10 
mM compound stock in DMSO was transferred into 70 l of serum-free RPMI-1640. 60 
l of medium containing each test compound was then withdrawn from the plates using 
a 384-well tip cartridge, leaving 10 l of each compound at 14.28 M. Cells were 
harvested at a density of 1-million cells/mL in RPMI-1640, supplemented with 10% CD-
FBS. A 1:500 dilution of 17β-Estradiol (E2) in ethanol (EtOH) and a vehicle-ethanol 
control, was added to the (+)E2 and (-)E2 cell stocks, respectively. Cell were plated at a 
density of 10,000 cells/well by pipetting 10 l of cells into each well using a Matrix 
Wellmate dispenser The final concentration of test compounds was 7.14 M. The 
screening medium contained 0.1% (v/v) EtOH, 0.07% (v/v) DMSO, and 10 nM E2. 
Plates were centrifuged for 2 minutes at 500 rpm, and incubated for 24 hours (37o/5% 
CO2). 
“Hits” from the primary HTS-screen were reconfirmed by diluting 10 mM 
compound stocks in DMSO to 20 M in serum-free RPMI-1640. Cells were harvested at 
a density of 1-million cells/mL in RPMI-1640, supplemented with 10% CD-FBS. A 1:500 
dilution of 17β-Estradiol (E2) in ethanol (EtOH) and a vehicle-ethanol control, was 
added to the (+)E2 and (-)E2 cell stocks, respectively. Cells were plated at a density of 
10,000 cells/well by pipetting 10 l of cells into each well. The final concentration of test 
compounds was 10 M and the medium contained 0.1% (v/v) EtOH, 0.1% (v/v) DMSO, 
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and 10 nM E2. Plates were centrifuged for 2 minutes at 500 rpm, and incubated for 24 
hours (37o /5% CO2).   
All plates were frozen at -20 oC overnight following the 24-hour incubation, and 
thawed to room temperature. 10 l of BrightGlow reagent (Promega, WI) was added to 
each well, and allowed to incubate for 15 minutes on the bench before measuring 
luminescence.  
 
96-Well Luciferase Assays 
5-6 days before the experiment T47D-KBluc cells were subcultured and plated at 
high density (about 30-40% confluence) in RPMI1640 + 10% FBS. 2 days later, the 
medium was changed to RPMI +10% CD-FBS. After 3 or 4 days with a medium change 
on day 2 the cells were harvested, counted and 50,000 cells in 100 l of medium were 
added to each well of a 96-well white-wall-clear bottom plate (BD Biosciences, NJ) in 
RPMI + 10% CD-CS. The medium was replaced the next day with medium containing 
the test compounds with or without hormone. After 24 hours, the medium was aspirated 
off, and 30 l of Bright Glow reagent (Promega, WI) was added. To help lyse the cells, 
the plate was placed on a shaker for 5 min. To remove any bubbles in the wells, the 
plate was subject to centrifugation at 2500 RPM for 2 min.  
 
MTS Growth Assays 
29 
 
Cells were harvested and plated in 96-well plates at a density of 1,000 cells/well. 
MCF-7 cells were plated into MEM, supplemented with 10% CD-Calf serum; T47D cells 
were plated into MEM, supplemented with 10% CD-FBS; and MDA-MB-231 cells were 
plated into MEM, supplemented with 10% FBS. The medium was replaced with 
treatment medium the following day, and plates were incubated at 37o C in 5% CO2 for 
3 days. 20 μl of CellTiter 96 Aqueous One Solution Reagent (Promega, WI) was added 
to each well and the cells were incubated at 37o C in 5% CO2 for 1 hour. A490 was 
then measured to assess cell viability. For each cell line, cell number was calculated 
from a standard curve of the number of cells plated versus A490 (12). 
 
Western Blotting 
Cells were trypsinized, resuspended in MEM supplemented with 10% CD-Calf 
serum and plated into 6-well plates at a density of 300,000 cells/well. The medium was 
replaced with treatment medium the following day, and the cells were treated for 24 
hours. The cells were washed in ice-cold PBS and whole-cell extracts were prepared in 
lysis buffer containing: 1x radioimmunoprecipitation assay buffer, 1 mM EGTA, 30 mM 
NaF, 2.5 mM sodium pyrophosphate, 1 mM sodium orhovanadate, 1 mM β-glycerol 
phosphate, 1 mM phenylmetholsulfonyl fluoride, and 1 tablet of protease inhibitor 
cocktail (Roche, IN). Cells were collected, and debris was pelleted by centrifugation at 
15,000 x g for 10 min at 4o C. The supernatants were collected, and stored at -20o C. 20 
μg of total protein was loaded onto 10% (v/v) SDS-PAGE gels, separated, and 
transferred to nitrocellulose. Membranes were incubated with monoclonal ER [6F11] 
antibody (Biocare Medical, CA) or control monoclonal α-Tubulin antibody (Sigma, MO). 
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Bound antibodies were detected using horseradish peroxidase-conjugated secondary 
antibodies and chemiluminescent immunodetection with an ECL Detection Kit (GE 
Healthcare, NJ), and were visualized using a PhosphorImager. 
 
qRT-PCR 
pS2 mRNA levels were analyzed by quantitative real-time reverse transcriptase-
polymerase chain reaction (qRT-PCR). RNAs were extracted with TRIzol reagent, 
purified with the RNAeasy mini-kit (QIAGEN, CA), and 0.5 g of RNA was reverse 
transcribed using a DyNAmo cDNA synthesis kit (Finnzymes, Finland). 50 ng of the 
cDNA product was added to 1 l of forward and reverse primer mix (10 μM). Primers 
used in qRT-PCR were: pS2, forward (5’-ACCGGACACCTCAGACACG) and reverse 
(5’-CTGTGTTGTGAGCCGAGGC); 36B4, forward (5’-GTGTTCGACAATGGCAGCAT) 
and reverse (5’-GACACCCTCCAGGAAGCGA). The fold change in expression of each 
gene was calculated using the ∆∆Ct method with 36B4 as the internal control. 
 
Data Analysis 
Compounds that inhibited the (ERE)3-luciferase reporter in the primary HTS-
screen by more than 50% were designated as “Hits”. Inhibition of E2-ER-mediated 
gene expression was calculated as follows:   
Eq. (1) 
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Compounds were screened in parallel for their ability to inhibit a prostate specific 
antigen (PSA)-luciferase reporter induced by dihydrotestosterone AR in stably 
transfected HeLa cells (12). Inhibition of DHT-AR-mediated gene expression was 
calculated as follows: 
Eq. (2) 
Reconfirmed “Hits” were evaluated for their ability to inhibit E2-ER stimulated 
proliferation of ER positive breast cancer cells using a cut-off of 50% to classify 
compounds as inhibitors of E2-ER-stimulated cell proliferation. Percent inhibition of E2-
ER-stimulated proliferation of MCF-7 cell and T47D cells growth was calculated as 
follows:         
     Eq. (3) 
Compounds were also evaluated for their ability to inhibit ER negative MDA-
MB-231. Compounds were classified as “non-toxic”, if they inhibited growth of the 
control ER negative MDA-MB-231 cell by <30%, or if the cell growth inhibition was 
more than two-fold greater in the ER positive cell lines compared to the MDA-MB-231 
cells. (Inhibition of E2-dependent growth cannot exceed 100% for this calculation. Thus 
all compounds inhibiting MDA-MB-231 cell growth by more than 50% were classified as 
“toxic”). Percent inhibition of MDA-MB-231 cell growth was calculated as follows. 
                                           Eq. (4) 
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Z’ values were calculated, as previously described (13).  
 
Results 
A Cell-based Screen for Inhibitors of E2-ERα Induction of an (ERE)3-Luciferase 
Reporter Gene 
Regulation of nuclear gene expression is central to the ability of estrogens bound 
to ER to induce proliferation of breast cancer cells. The widely used breast cancer 
therapeutic tamoxifen acts by competing with estrogens for binding to ER and 
interfering with recruitment of coactivators critical for ER-mediated gene expression.  
To identify novel small molecules that directly or indirectly inhibit E2-ER-mediated gene 
expression, a cell-based primary screen was developed using ER positive T47D 
human breast cancer cells stably transfected to express a luciferase reporter whose 
expression is driven by 3 copies of the consensus estrogen response element (ERE)3-
luciferase (11).  Dose-response studies show that E2 robustly and reproducibly induces 
expression of the luciferase reporter (Fig. 1A). Some cell-based luciferase reporter 
screens have not been robust screens, as indicated by a low Z’-factor (14). In HTS, our 
assay was robust with a mean Z’-factor of 0.55 (Fig. 1B).  
In some screens, a constitutively active luciferase reporter can provide a useful 
indicator of the specificity and toxicity of potential small molecule inhibitors. However, 
small molecule inhibitors of E2-ER induced gene expression should also inhibit the 
proliferation of ER positive human breast cancer cells, and might thereby decrease the 
activity of a constitutively active Renilla luciferase internal standard. To test this, we 
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compared the effect of several well-established, specific and non-toxic, inhibitors of ER 
with a mildly toxic compound identified in our follow-on assays. The well known 
therapeutics tamoxifen, raloxifene and faslodex and the toxic compound all produced 
similar substantial declines in expression of the constitutively active luciferase reporter 
gene (Fig. 2).  Since the constitutively active luciferase could not distinguish toxic 
compounds from bona-fide ER inhibitors, we used tiered assays to filter out toxic 
compounds.  
Small molecule “hits” were first screened for inhibition of dihydrotestosterone 
(DHT)-androgen receptor (AR) induction of a prostate specific antigen-luciferase (ARE-
luciferase) reporter in stably transfected HeLa cells (12). This provided a way to initially 
flag compounds as toxic, which was later reconfirmed in subsequent toxicity assays. A 
second reporter also functioned as a crude method for assessing the nuclear receptor 
specificity of small molecules, given that ER and AR share a high degree of structure 
homology and conservation in upstream signaling pathways. It also provides a way to 
detect inhibitors of luciferase enzyme activity. Alternatively, inhibitors of luciferase 
enzyme activity could have been detected by growing the T47D-kBLuc cells in the 
presence of estrogen alone, lysing the cells, and then adding the small molecule being 
tested and the luciferase reagent.  
Compounds were considered hits in the primary screen if, at a concentration of 
7.1 M, they reduced luciferase units by at least 50%. All compounds reaching the 50% 
cut-off had reached statistical significance, as defined by ±3 SD from the negative 
reference. In order to evaluate the effective size of inhibition, strictly standardized mean 
difference was used as a secondary metric in lead selection. 
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Evaluation of 75 Verified inhibitors of E2-ERα Induction of the (ERE)3-Luciferase 
Reporter Gene 
To evaluate the effectiveness of our luciferase-based assays in identifying useful 
lead inhibitors that selectively inhibit E2-ER induced proliferation of ER positive 
human breast cancer cells, we characterized a randomly selected set of 75 hits from a 
subset of approximately 16,000 compounds. Data from the primary HTS screen for 
each compound screened at 7.1 μM is shown for inhibition of (ERE)3-luciferase and 
ARE-luciferase in Figure 3, and in terms of SSMD in Figure 4. Compounds were further 
characterized in terms of their effects on cell growth (Fig. 5A and 5B) after reconfirming 
the compounds as inhibitors of (ERE)3-luciferase activity at 10 μM (Fig. 5C, T47D-
KBluc; Table 1). Each of the 75 compounds was evaluated at 10 M for its ability to 
inhibit E2-dependent proliferation of ER positive MCF-7 and T47D, human breast 
cancer cells and for non-specific toxicity as evidenced by inhibition of the proliferation of 
control ER negative MDA-MB-231 cells (Fig 5C, T47D and MCF-7). This is a rigorous 
control as small molecules readily inhibit proliferation of MDA-MB-231 cells (12). Based 
on their effects on E2-ER-dependent and E2-ER-independent cell proliferation, the 
compounds clustered into 4 distinct categories. (i) “Lead” compounds that inhibited 
proliferation of both ERα positive cell lines with minimal effects on proliferation of the 
ER negative MDA-MB-231 cells (Fig. 5C, 1-8); (ii) “Cell Selective” compounds that 
inhibited proliferation of only one of the two ERα positive cell lines with minimal effects 
on proliferation of the ER negative MDA-MB-231 cells (Fig. 5C, 9-17); (iii) “No Growth 
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Inhibition” compounds that exhibited little or no ability to inhibit E2-ER-stimulated 
proliferation (Fig. 5C, 18-38); and (iv) “Toxic” compounds that inhibited proliferation of 
the ER negative MDA-MB-231 cells (Fig. 5C, 39-75). The toxic compounds could be 
further subdivided into “Toxic to All” compounds that were toxic in all three cell lines 
(Fig. 5C, 39-68) and “Toxic to 231” compounds that were primarily toxic in the MDA-MB-
231 cells (Fig. 5C, 69-75). 
 
Detailed Characterization of Selected Compounds 
We examined the properties of four structurally unrelated representative 
compounds in more detail (Fig. 6A). For the four compounds that were selected, we 
performed dose-response studies of inhibition of E2-ER-mediated expression of the 
(ERE)3-luciferase reporter (Fig. 6B) and of E2-ER-stimulated proliferation (Fig. 7).  
At all concentrations tested, Compound 45, strongly inhibited proliferation of both 
the ER positive MCF-7 and T47D cells and the ER negative MDA-MB-231 cells (Fig. 
7B). Its overall toxicity is responsible for the ability of Compound 45 to inhibit expression 
of the (ERE)3-luciferase reporter (Fig. 6B). The shorter time cells were exposed to 
compounds in the reporter assay, 1 day as opposed to 3 days, likely accounts for the 
more limited inhibition seen in the reporter assay. Since Compound 45 was toxic to all 
the cells across a broad range of concentrations (Fig. 7B), it was not analyzed further. 
Compound 4 was identified as a potential selective inhibitor of ER action (Fig. 5C). 
Compound 4 elicited a dose-dependent inhibition of E2-ER-induced (ERE)3-luciferase 
with an IC50 of ~4.0 M (Fig. 6B). From 2.5-10 M, Compound 4 selectively inhibited 
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proliferation of the ER positive cells compared to the ER negative MDA-MB-231 cells 
(Fig. 7A). The IC50s for inhibition of the proliferation of the ERα positive cells were 3.7 
and 1.7 M for the MCF-7 and T47D cells, respectively and 12.8 M for the ER 
negative MDA-MB-231 cells (Fig. 7A). We also evaluated two small molecules that 
selectively inhibited one of the two ER positive cell lines. Compound 14 was a 
moderately effective inhibitor of (ERE)3-luciferase with an IC50 of ~11.1 M (Fig. 6B). 
While Compound 14 had little effect on cell proliferation at 1-5 M, at concentrations 
above 10 M it robustly inhibited proliferation of the T47D cells with little effect on the 
MCF-7 cells (Fig. 7C). Compound 11 inhibited (ERE)3-luciferase with an IC50 of ~3.4 M 
(Fig. 6B). Compound 11 stimulated growth of the T47D cells, but strongly inhibited 
growth of the MCF-7 cells and exhibited moderate dose-independent inhibition of the 
MDA-MB-231 cells (Fig. 7D). Thus, this unusual small molecule has opposite effects on 
the proliferation of the two ER positive cell lines. 
 
Effect of Selected Compounds on the Level of ERα and on Estrogen induction of 
pS2 mRNA 
Several ER inhibitors act in part by decreasing the level of ER (12, 15). We 
therefore examined whether the lead inhibitor, Compound 4 and the two cell type 
selective inhibitors, Compounds 11 and 14, influence levels of ER in T47D and MCF-7 
cells. ICI 182,780/fulvestrant/faslodex and TPSF are competitive and non-competitive 
ERα inhibitors known to function in part by reducing ER levels (12, 15, 16). As 
expected, ICI 182,780 and TPSF dramatically reduced ER levels in the MCF-7 and 
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T47D cells (Fig. 8A and 8B). The lead ER inhibitor, Compound 4, strongly reduced 
ER levels in both cell lines. In contrast, the two cell line selective inhibitors either had 
no effect (Compound 14) or elicited a small decline in ER levels (Compound 11) (Fig. 
8A and 8B). 
We carried out our initial assays for inhibition of E2-ER-mediated gene 
expression using a stably transfected (ERE)3-luciferase reporter. While this stably 
transfected reporter gene will exhibit a more nearly native chromatin structure than a 
transiently transfected reporter gene, it is still likely different from the chromatin 
structure of a true endogenous gene. We therefore examined the ability of the three 
small molecules to inhibit E2-ER-induction of the widely studied endogenous pS2 gene 
in the same cell line in which we performed the (ERE)3-luciferase assays (17, 18). We 
used quantitative RT-PCR to measure pS2 mRNA levels (Fig. 8C). E2 induced pS2 
mRNA 5.8 fold. The induction of pS2 mRNA was largely blocked by the control ER 
inhibitors ICI 182,780 and TPSF and by the lead inhibitor reported here, Compound 4. 
There was good agreement between the ability of 5 M of Compound 4 to inhibit E2-
ER-induction of the (ERE)3-luciferase reporter gene and the endogenous pS2 mRNA 
(~76% inhibition of (ERE)3-luciferase (Fig. 6B) and ~67% inhibition of pS2 mRNA (Fig. 
8C)). In contrast, the weak inhibitor of (ERE)3-luciferase, Compound 14 did not inhibit E2 
induction of pS2 mRNA and 10 M Compound 11 inhibited induction of pS2 mRNA by 
~35% (Fig. 8C). While the lead compound, which inhibited proliferation in both ER 
positive cell lines, robustly inhibited E2 induction of the endogenous pS2 mRNA, the 2 
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cell selective inhibitors were ineffective and are unlikely to act by directly targeting ER 
action. 
 
Discussion 
In evaluating a single reporter luciferase-based assay as a surrogate assay for 
estrogen-induced proliferation of cancer cells, two potential sources of off-target effects 
stand out. Small molecules that inhibit because they exhibit direct interaction with 
luciferase and small molecules that are broadly toxic. Both types of small molecule can 
reduce luciferase activity and be scored as hits in the primary screen (2, 3). 
Approximately 37% (28 of 75, Fig. 5) of the hits identified in the luciferase assay 
did not reach the cutoff for inhibition of E2-ER-stimulated proliferation in both, MCF-7 
and T47D, human breast cancer cells. This included the 21 compounds in the “No 
Growth Inhibition” category (Fig. 5, 18-37) and the 7 compounds in the “Toxic” category 
that only inhibited cell growth in MDA-MB-231 cells (Fig. 5, 69-75). Nearly all of the 
latter compounds (6 of 7) inhibited cell growth modestly (>25%) in both ER positive 
breast cancer cell lines. The more pronounced effects on cell growth in the ER 
negative MDA-MB-231 cells can be attributed to the higher sensitivity of this cell line to 
damage (12).  The “No Growth” inhibitors, could be further sub-classified as (i) 
compounds that modestly inhibited cell proliferation, but did not reach the 50% cutoff 
(Fig. 5, 18-28) or (ii) compounds that exhibited little or no ability to inhibit E2-ER-
stimulated proliferation of the breast cancer cells (Fig. 5, 29-38). Partial growth inhibition 
may reflect different dose-response curves for inhibition of gene expression and cell 
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proliferation. Consistent with this idea, the concentration of the non-competitive ER 
inhibitor TPSF required to inhibit cell proliferation is ~3 fold higher than is required to 
inhibit the luciferase reporter (12). Compounds that showed no ability to inhibit E2-ER-
stimulated proliferation of the breast cancer cells might be acting as direct inhibitors of 
luciferase enzyme activity. However, 8 of the 9 compounds that failed to inhibit growth 
(Fig. 5, 29-38), also failed to significantly inhibit the DHT-AR induced PSA-luciferase 
reporter (Fig. 3, 29-38). This suggests that these compounds are not functioning as 
luciferase inhibitors. 
Approximately 49% (37 of 75, Fig. 5) of the compounds were toxic, as a result of their 
ability to inhibit cell growth in ER negative MDA-MB-231 cells. Approximately 81% of 
the toxic compounds displayed global toxicity (Fig 5, 39-68), while 19% selectively 
inhibited MDA-MB-231 cells (Fig. 5, 69-75). The large number of toxic compounds is 
readily attributed to the high sensitivity of MDA-MB-231 cells to damage, the rigorous 4-
day treatment interval used to assess for growth effects, and the more stringent growth 
inhibition cut-offs used to classify compounds as  “toxic” (30% cut-off compared to 50% 
cut-off for ER positive cell lines). Our data suggests that use of an alternative reporter 
system in parallel with the primary screen can provide useful predictive value in 
identifying potentially toxic compounds. Approximately 70% of the compounds 
considered toxic inhibited the ARE-luciferase reporter by >30% (Fig. 3, 39–75). These 
compounds all displayed SSMD scores <–2 (Fig. 4, 39–75), demonstrating that these 
reductions in ARE-luciferase were statistically significant at the 95% confidence level. 
Conversely, only 11% of “nontoxic” compounds inhibited the DHT-AR-induced ARE-
luciferase reporter by >30% (Fig. 3, 1–38). Yet, 3 of these nontoxic compounds 
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represent “lead” compounds (Fig. 3, 5, and 8). This suggests that data from a 
secondary reporter system should aid in evaluating toxicity and should be used in 
concert with additional toxicity assays, rather than serve as a rigid cutoff for evaluating 
candidate leads. The identification of leads that inhibit both reporters may reflect 
modulation of receptor activity via direct interactions with small molecules at structurally 
homologous sites or through indirect interaction via targeting-conserved upstream 
signaling pathways. Importantly, the ARE-reporter provides a preliminary measure of 
nuclear receptor specificity for small molecule “leads” and provides a starting point for 
tailoring subsequent assays toward subsets of “leads.”   
 
Perhaps most surprising was our finding that some small molecule hits from the 
ERE-luc reporter assay inhibited proliferation in either T47D cells or MCF-7 cells, but 
not in both cell lines. MCF-7 and T47D cells are the most widely used lines of ER 
positive breast cancer cells. These cell lines were independently derived from different 
tumors. Since the hits were identified using a primary screen for inhibitors of ERE-luc 
expression in stably transfected T47D cells, and T47D cells contain less ER than 
MCF-7 cells (19), we anticipated we might identify small molecules that were more 
effective in T47D cells than MCF-7 cells. Instead we identified some small molecules 
that were toxic in MDA-MB-231 cells but only damaged one of the two cell lines and a 
few small molecules that preferentially inhibited proliferation of each of the cell lines 
without damaging MDA-MB-231 cells. Compound 14 exhibited a dose-dependent 
inhibition of the proliferation of T47D cells with little effect on proliferation of MCF-7 
cells. At 10 M, Compound 14 inhibited proliferation of the T47D cells by ~81% with no 
effect on proliferation of the MCF-7 cells or MDA-MB-231 cells (Fig. 7C). In contrast, 
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Compound 11 killed all the MCF-7 cells and actually stimulated estrogen-dependent 
growth of the T47D cells from 2.5-20 M (Fig. 7D). The surprising properties of 
Compound 11 demonstrate that effects on cell proliferation can be entirely dissociated 
from effects on reporter gene expression. It is unlikely that Compounds 11 and 14 
directly target ER action as they had little or no ability to inhibit estrogen induction of 
pS2 mRNA in the same T47D line used for the luciferase assays (Fig. 8C). These data 
illustrate the importance of early evaluation of primary hits using more than one cell line. 
About 10% of the primary hits from the luciferase-screen represented leads that 
inhibited estrogen-dependent proliferation of both the MCF-7 and T47D cells with 
minimal effects on proliferation of the ER negative MDA-MB-231 cells (Fig. 5, 1-8). 
From 1-5 M, Compound 4 elicited progressive inhibition of the proliferation of MCF-7 
and T47D cells with little effect on proliferation of MDA-MB-231 cells (Fig. 7A). Since 
Compound 4 shows some toxicity in MDA-MB-231 cells at 10 M, we used 5 M to test 
its effect on estrogen induction of pS2 mRNA. Consistent with its effect on the ERE-luc 
reporter and on E2-ER-stimulated cell proliferation, Compound 4 effectively inhibited 
induction of pS2 mRNA and is a lead compound for further development. 
The application of cell-based assays in HTS remains inherently challenging. The 
large number of biological targets and high degree of crosstalk between integrated 
signaling pathways predisposes cell-based assays to higher “Hit” frequencies, lower 
confirmation rates, and higher numbers of toxic compounds in follow-up assays (20, 
21). Approximately 10% of the verified hits from the luciferase-based-screen ultimately 
met our end-point for selective inhibition of estrogen-dependent proliferation of ER 
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positive cell lines. While this might seem to argue for a cell-proliferation based screen, a 
primary screen based on inhibition of cell proliferation would have exposed many of the 
same issues. Since single cell proliferation assays do not usually distinguish between 
toxic compounds and those targeting the pathway of interest, many of the hits from a 
proliferation-based screen would have emerged as toxic when tested in a control cell 
line. Our finding that some compounds exhibit cell line specific inhibition of estrogen-
dependent proliferation means that compounds identified in a single cell line may still 
fail in other cell lines because they do not target ER. In our hands, assays for 
estrogen-dependent cell proliferation assays in 384 well plates exhibited less precision 
and reproducibility than luciferase-based assays and require several days compared to 
one day for luciferase assays. While luciferase-based assays offer the advantage of 
improved efficiency in HTS, assay interference remains an important obstacle to 
generating high quality leads. Although the role of assay interference in our screen is 
largely unknown, the coupling of multiple cell proliferation assays to the primary screen 
provided an effective filter for rapidly eliminating compounds that lack bioactivity. 
Alternatively, this empirically driven approach of asking cells to tell us what small 
molecules are capable of inhibiting E2-ER-stimulated proliferation, provides a way to 
select for bioactive compounds, independent of their ability to elicit assay interference in 
the primary screen. Recent studies have shown that several important small molecules 
function as dual inhibitors of ATP-dependent kinases and luciferases, including 
resveratrol and the MEK1/2 inhibitor, PD090859 (22-24). Since the role of E2-ER in 
gene expression is essential to stimulating breast cancer cell proliferation, and a 
number of pathways can modulate ER transcriptional activity through post-translational 
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modifications (25), our screen would not preclude identification of such bioactive 
compounds. Small molecules generally target several sites in cells, and through signal 
integration and unintended crosstalk, can elicit toxicity that is readily observed in 
downstream readouts like E2-ER-mediated gene expression. Carrying out multiple cell 
proliferation assays, using cells with and without the target, provides a very effective 
toxicity filter. This is reflected by the large numbers of toxic compounds we identified. 
With appropriate follow-on verification assays carried out in multiple cell lines, a 
luciferase-based primary screen represents a useful surrogate assay for a more 
complex process, such as hormone-stimulated cell proliferation. 
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Figure 2.1. The ERE-luciferase reporter assay. (A) Dose response study of E2-ER 
induction of ERE-luciferase. The data represents the average + S.E.M. of quadruplicate 
assays carried out in 96 well plates. (B) Assessment of screen robustness using Z’-
factor. Z’-factor for each plate in the overall screen (●), and the overall Z’ value for the 
entire screen are denoted above. 
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Figure 2.2. Comparison of the effects of well-established ER-Inhibitors and a 
toxic compound on luciferase reporters. Treatment of cells with well-established 
ER-Inhibitors and a toxic compound significantly inhibited (A) (ERE)3-firefly luciferase 
and (B) SV40-renilla luciferase activity. T47D cells were maintained for 3 days in 10% 
CD-FBS prior to transfecting cells with 0.4 μg of (ERE)4-firefly Luciferase and 2.5 ng 
SV40-renilla luciferase for 24 hours. Cell were treated after transfection for 24 hours 
with a ethanol-vehicle control (-E2), 1 nM 17β-Estradiol (E2), or a combination of 1 nM 
E2 and either 1 μM 4-Hydroxy-Tamoxifen (TAM),1 μM Raloxifene (RAL), 1 μM ICI 
182,780/Fulvestrant (ICI), 1 μM  TPSF, or 10 μM of Compound 45 (toxic compound). 
Cells were harvested and assayed for firefly and renilla luciferase activity. Data 
represents the mean ± S.E.M. for three separate experiments. 
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Figure 2.3. Primary screening data for the 75 representative compounds selected 
for further characterization. For each compound, percent inhibition of DHT-AR -
stimulated PSA-luciferase activity (black bars) and E2-ER-stimulated ERE-luciferase 
activity (grey bars) is shown. 
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Figure 2.4 Strictly standardized mean difference (SSMD) scores for the effects of 
the 75 selected small molecules. SSMD score on (A) E2-ER-induced (ERE)3-
luciferase and (B) DHT-AR-induced ARE-luciferase. SSMD values of ±1, ±2, and ±3 
correlate with d+-probability boundaries of 0.5, 0.95, and 0.975 respectively (17). SSMD 
scores less than -2 reflect statistically significant reductions in luciferase activity at the 
95% confidence level. The population value of SSMD was used to organize small 
molecules into categories based on their strength of inhibition, as described previously 
(17). 
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Figure 2.5. Summary of assays used to evaluate inhibitors of ER-mediated gene 
expression as a surrogate marker for inhibitors of E2-dependent growth. (A) Flow 
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chart showing the breakdown by category of compounds screened for reporter activity 
and growth inhibition. (B) Summary of the classes of compounds identified. (C) 
Compounds were further assessed for (from top to bottom) their ability to inhibit ERE-
luciferase activity (T47D-KBluc), growth of ER- MDA-MB-231 breast cancer cells 
(MDA-MB-231), E2-ER-dependent proliferation of ER+ T47D, and MCF-7 breast 
cancer cells. Each assay was carried out in triplicate, and mean inhibition levels are 
denoted above. Numerical data is in Table 1. 
 
 
 
Figure 2.6. Characterization of representative inhibitors. (A) Structures of the 
compounds that were tested selected. (B) Dose-response curves for inhibition of ERE-
luciferase by selected compounds.T47D-KBluc cells were maintained for 3 days in 10% 
CD-FBS and then incubated for 24 hours in the presence of 10 nM E2 and the indicated 
concentrations of the test compounds. Cells were harvested and assayed for luciferase 
activity. 
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Figure 2.7. Dose-response studies of the effects of the inhibitors on cell 
proliferation. Dose response studies were used to evaluate the effect on the E2-ER-
dependent proliferation of MCF-7 and T47D cells and on the growth of ER negative 
MDA-MB-231 for (A) Compound 4, (B) Compound 45, (C) Compound 14, and (D) 
Compound 11. Cells received the indicated concentrations of each inhibitor in DMSO. 
After 3.5 days cell number was quantified by MTS. ER+ cell lines were also treated 
with ICI 182,780, a known ER antagonist. Mean percent growth inhibition is 
representative of triplicate assays + S. E.M.  
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Figure 2.8. Effect of the 3 inhibitors on ER levels and on the induction of pS2 
mRNA. The effects of the three compounds on the level of ER was evaluated in 
Western blots of extracts from (A) T47D cells and (B) MCF-7 cells. ICI 182,780 (ICI) 
and TPSF, known down-regulators of ER were used as controls. (C) Compounds were 
tested for their ability to inhibit E2-ER induction of pS2 mRNA. pS2 mRNA levels were 
quantified by qRT-PCR, following  24-hour treatment of T47D-KBluc cells with 10 nM E2 
and 5 M of compound 4. 
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Table 2.1. Percent inhibition and S.E.M. values for the seventy-five small 
molecules further characterized. The classification of each compound is denoted 
using the following symbols: "L" denotes a "Lead" inhibitor, "S" denotes a "Cell 
Selective" inhibitor, "NG" denotes a "No growth" inhibitor, "TA" denotes a "Toxic" 
inhibitor, and "T-231" denotes a "Toxic-231 Only" inhibitors. 
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Table 2.1 Continued… 
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CHAPTER 3 
 
ANTICIPATORY ESTROGEN ACTIVATION OF THE UNFOLDED 
PROTEIN RESPONSE IS LINKED TO CELL PROLIFERATION AND 
POOR SURVIVAL IN ESTROGEN RECEPTOR  POSITIVE BREAST 
CANCER CELLS 2 
 
Abstract 
In response to cell stress, cancer cells often activate the endoplasmic reticulum 
(EnR) stress sensor, the unfolded protein response (UPR). Little was known about the 
potential role in cancer of a different mode of UPR activation; anticipatory activation of 
the UPR prior to accumulation of unfolded protein or cell stress. We show that estrogen, 
acting via estrogen receptor  (ER), induces rapid anticipatory activation of the UPR, 
resulting in increased production of the antiapoptotic chaperone BiP/GRP78, preparing 
cancer cells for the increased protein production required for subsequent estrogen-ER 
induced cell proliferation. In ER containing cancer cells, the estrogen, 17-estradiol (E2) 
activates the UPR through a phospholipase C  (PLC)-mediated opening of EnR IP3R 
calcium channels, enabling passage of calcium from the lumen of the EnR into the 
cytosol. siRNA knockdown of ER blocked the estrogen-mediated increase in cytosol 
calcium and UPR activation. Knockdown or inhibition of PLC, or of IP3R, strongly 
                                                          
2 This chapter appeared in its entirety in Oncogene. Andruska N, Zheng X, Yang X, Helferich WG, 
Shapiro DJ. (2014) Anticipatory estrogen activation of the unfolded protein response is linked to cell 
proliferation and poor survival in estrogen receptor α-positive breast cancer. Oncogene. 33 (advance 
online publication, September 29, 2013. This article is reprinted with the permission of the publisher. 
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inhibited the estrogen-mediated increases in cytosol calcium, UPR activation and cell 
proliferation. E2-ER activates all three arms of the UPR in breast and ovarian cancer 
cells in culture and in a mouse xenograft. Knockdown of ATF6, which regulates UPR 
chaperones, blocked estrogen induction of BiP and strongly inhibited E2-ER stimulated 
cell proliferation. Mild and transient UPR activation by estrogen promotes an adaptive 
UPR response that protects cells against subsequent UPR-mediated apoptosis. Analysis 
of data from ER positive breast cancers demonstrates elevated expression of a UPR 
gene signature that is a powerful new prognostic marker tightly correlated with 
subsequent resistance to tamoxifen therapy, reduced time to recurrence and poor 
survival. Thus, as an early component of the E2-ER proliferation program, the mitogen 
estrogen, drives rapid anticipatory activation of the UPR. Anticipatory activation of the 
UPR is a new role for estrogens in cancer cell proliferation and resistance to therapy. 
 
Introduction 
Estrogens, acting via estrogen receptor  (ER), stimulate cell proliferation and 
tumor growth (1-3). The importance of estrogens and ER in breast cancer is illustrated 
by the central role of endocrine therapy targeting estrogens and ER in treatment of 
ER+ breast cancer (1-5). To help fold and sort the increased protein required for 
estrogen-ER induced cell proliferation, cells must increase chaperone levels. The 
endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR) 
monitors and maintains protein-folding homeostasis (6, 7). The UPR responds to 
misfolded proteins, or other forms of stress, by activating three signal transduction 
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pathways, which reduce protein production and increase EnR protein-folding capacity. 
Protein production is regulated by autophosphorylation of the stress-activated 
transmembrane kinase, PERK (6, 7).  P-PERK phosphorylates eukaryotic initiation 
factor 2 (eIF2), resulting in transient inhibition of protein synthesis. The other UPR 
arms initiate with proteolytic activation of the transcription factor ATF6, leading to 
increased chaperone production and activation of the EnR splicing factor IRE1, which 
alternatively splices the transcription factor XBP1, leading to production of active 
spliced-XBP1, increased protein folding capacity and altered mRNA decay and 
translation (6, 7). 
The UPR is usually inactive in normal cells, but is overexpressed in several 
cancers (8). Chronic UPR activation leads to increased expression of EnR chaperones, 
such as BiP (GRP78/HSAP5), p58IPK and calreticulin that facilitate protein folding and 
promote survival, proliferation, angiogenesis, and resistance to chemotherapy and 
endocrine therapy (9-12). In the widely studied “reactive mode”, the UPR in tumor cells 
is activated in response to accumulation of stress from rapid cell division, hypoxia and 
therapy. A few studies in immune cells describe a different type of UPR activation; in 
this “anticipatory mode”, the UPR is activated in the absence of EnR stress and prior to 
the accumulation of unfolded proteins (13, 14). We explored whether estrogen induces 
anticipatory activation of the UPR in the absence of EnR stress, increasing protein 
folding capacity prior to the increased protein production and protein folding load that 
accompanies activation of the genomic estrogen-ER cell proliferation program. 
Previous studies of the UPR and of estrogen-ER action focused on the estrogen-
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inducible UPR gene, XBP1. XBP1 binds to and activates ER; XBP1 expression is 
associated with tamoxifen resistance in ER+ breast cancer (15-18). 
The plasma membrane enzyme phospholipase C  (PLC) hydrolyzes PIP2 to 
diacyglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). We show that the mitogen 
estrogen, 17-estradiol (E2), acting through a rapid extranuclear action of ER, elicits a 
PLC-mediated opening of EnR IP3R calcium channels, increasing cytosol calcium and 
triggering anticipatory activation of each arm of the UPR. Opening the IP3R calcium 
channel and activating the ATF6 arm of the UPR, resulting in BiP induction, are 
important for subsequent E2-ER induced cell proliferation. Consistent with an important 
role in cancer for anticipatory activation of the UPR, analysis of data from ~1,000 ER+ 
breast cancer patients demonstrates that elevated expression of a UPR gene signature 
is tightly correlated with subsequent resistance to tamoxifen therapy, time to tumor 
recurrence and poor survival.  
 
Materials and Methods 
Cell Culture and Reagents 
Cell culture medium and conditions were previously described (19-21). MCF-7, 
T47D, and T47D-kBluc cells were obtained from the ATCC. Drs. S. Kaufmann and K. 
Korach provided PEO4 cells and BG-1 cells, respectively. E2, 4-OHT, U73122, 2-APB, 
and tunicamycin were from Sigma Aldrich. ICI 182,780 was from Tocris Biosciences 
and ryanodine was from Santa Cruz Biotechnology. Phospho-eIF2 (#3398), eIF2 
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(#5324), Phospho-PERK (#3179), PERK (#5683), and BiP (#3177) antibodies were 
from Cell Signaling. Pan-IP3R (sc-28613), XBP1 (sc-7160), and ER (sc-56836) 
antibodies were from Santa Cruz Biotechnology. Other antibodies used were ATF6 
(Imgenex) and β-Actin (Sigma). 
 
Cell Proliferation Assays 
Cells proliferation assays were carried out as described (19-21). 
 
Protein Synthesis 
Protein synthesis was evaluated by measuring incorporation of 35S-Methionine 
into newly synthesized protein. Cells were incubated in 96 well plates for 20 minutes 
with 3 Ci of 35S-methionine per well (PerkinElmer), lysed, and clarified by 
centrifugation. The appropriate volume, normalized to total protein, was spotted onto 
Whatman 540 filter paper discs and immersed in cold 10% TCA and washed in 5% 
TCA. Trapped protein was solubilized and filters counted. 
 
Calcium Imaging 
Cytoplasmic Ca2+ concentrations were measured using the calcium-sensitive 
dye, Fluo-4 AM (22, 23). Cells were grown on 35 mm-fluorodish plates (World Precision 
Instruments) for two days prior to experiments. Cells were loaded with 5 M Fluo-4 AM 
(Life Technologies) in buffer (140 mM NaCl, 4.7 mM KCl, 1.13 mM MgCl2, 10 mM 
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HEPES, 10 mM Glucose, pH = 7.4) for 30 minutes at 37 oC. The cells were washed 
three times with this buffer and incubated with either 2 mM or 0 mM CaCl2 for 10 
minutes. Images were captured for one minute to determine basal fluorescence 
intensity, and then the appropriate treatment was added. Measurements used a Zeiss 
LSM 700 confocal microscope with a Plan-Four 20X objective (N.A. = 0.8) and 488-nM 
laser excitation (7% power). Images were obtained through monitoring fluorescence 
emission at 525 nM, and analyzed with AxioVision and Zen software (Zeiss).  
 
Luciferase Assays, qRT-PCR, and siRNA Transfections 
Reporter gene assays and qRT-PCR were previously described (19, 20). siRNA 
knockdowns were performed using DharmaFECT1 Transfection Reagent and 100 nM 
ON-TARGETplus non-targeting pool or SMARTpools for ER (ESR1), PLC (PLCG1), 
PERK (EIF2AK3), ATF6 (ATF6), XBP1, or pan-IP3R (Dharmacon). The pan-IP3R 
SmartPool consisted of three individual SmartPools, each at 33 nM, directed against 
each isoform of the IP3R (ITPR1, ITPR2, and ITPR3).  
 
MCF-7 Xenograft 
Experiment were approved by the Institutional Animal Care Committee (IACUC) 
of the University of Illinois at Urbana-Champaign. The MCF-7 cell mouse xenograft 
model has been described previously (24). Estrogen pellets (1 mg:19 mg 
estrogen:cholesterol) were implanted into 30 athymic female OVX mice at 7 weeks of 
age. Three days later, 1 million MCF-7 human breast cancer cells suspended in 
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matrigel were subcutaneously injected into two sites on each flank, for a total of 4 
tumors per mouse. When average tumor size reached 17.6 mm2, E2 pellets were 
removed and a lower dose of E2 in sealed silastic tubing (1:31 estrogen:cholesterol, 3 
mg total weight) was implanted. When average tumor size reached 23.5 mm2, 15 mice 
retained E2 silastic tubes (+E2 group) and 15 mice received silastic tubes containing 
only cholesterol (-E2 group). Tumors were measured every 4 days with a caliper. Tumor 
cross sectional area was calculated as (a/2)*(b/2)*3.14, where a and b were the 
measured diameters of each tumor. On termination of the experiments mice were 
euthanized and tumors were excised. 
 
Tumor Microarray Data Analysis 
Analysis was performed using several publically available tumors cohorts. ER 
and UPR gene expression profiles of histologically normal breast epithelium 
(GSE20437) (25) were compared to IDC tumors from ER+ breast cancer patients 
(GSE20194). ER and UPR correlation analysis was performed on 278 invasive ductal 
carcinoma samples (GSE20194) (26). A “UPR Gene Signature” was constructed to 
carry out risk prediction analysis. The UPR gene signature was evaluated for its ability 
to predict: (i) tumor relapse in 261 early-stage ER+ breast cancers (GSE6532),37 (ii) 
tumor relapse in 474 ER+ patients receiving solely tamoxifen therapy for 5 years 
(GSE6532, GSE17705) (27, 28), and (iii) overall survival in a mixed-cohort of 236 breast 
cancer patients (GSE3494) (29). Microarray data analysis was performed using BRB 
ArrayTools (version 4.2.1) and R software version 2.13.2. Gene expression values from 
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CEL files were normalized by use of the standard quantile normalization method (30).  
Pearson correlation tests and Spearman log rank tests were used to determine gene 
expression correlation coefficients. Wald tests were used to test whether UPR genes 
were predictive of tumor recurrence and overall survival. Univariate and multivariate 
hazard ratios were estimated using Cox regression analysis. Covariates statistically 
significant in univariate analysis were further assessed in multivariate analysis. A patient 
was excluded from multivariate analysis, if data for one or more variables were missing. 
Risk prediction using the UPR gene signature was carried out using the supervised 
principle components method (31), and visualized using Kaplan-Meier plots and 
compared using log-rank tests. 
 
Statistical Analysis 
Calcium measurements are reported as mean ± SE. All other data is reported as 
mean ± S.E.M. Two-tailed student’s t-test used for comparisons between groups. One-
way ANOVA followed by Fisher’s LSD or Tukey’s post hoc test used for multiple 
comparisons. P < 0.05 was considered significant. 
 
Results 
Estrogen Activates all 3 Arms of the UPR 
To evaluate the ability of E2-ER to activate the UPR, we focused on production 
of spliced and modified proteins that result from activating the three arms of the UPR 
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(Fig. 1). E2 rapidly activated the IRE1 arm of the UPR, as shown by increases in 
spliced-XBP1 (sp-XBP1) mRNA in T47D and MCF-7 breast and PEO4 ovarian cancer 
cells (Fig. 2A and B), and by induction of downstream sp-XBP1 targets, SERP1 and 
ERDJ (Fig. 3A) (32). The antiestrogens ICI 182,780/Faslodex/fulvestrant (ICI) and 4-
hydroxytamoxifen, (4-OHT), which compete with E2 for binding to ER, blocked the E2-
mediated increase in sp-XBP1 (Fig. 2A). Consistent with E2-ER activating the IRE1 
arm of the UPR, RNAi knockdown of ER blocked E2-induction of sp-XBP1 mRNA (Fig. 
2C), and induction of GREB1 by nuclear E2-ER (Fig. 3B). 
We next assessed whether estrogen activates the ATF6 arm of the UPR. 
ATF6 is a 90 kDa protein (p90-ATF6) that translocates from the EnR to the Golgi in 
response to stress, where it undergoes proteolytic cleavage to its active 50 kDa form 
(p50-ATF6) (Fig. 1B) (6, 7, 33). Increased ATF6 proteolysis in T47D cells and PEO4 
cells demonstrates that E2-ER transiently activates the ATF6 arm of the UPR (Fig. 
2D and Fig. 3C). Since pretreatment with ICI, abolished the E2-mediated increase in 
p50-ATF6, this effect is mediated through ER (Fig. 2D). Active cleaved ATF6 
regulates induction of BiP and other EnR chaperones (33, 34). Consistent with this, 
ATF6 knockdown in T47D cells blocked BiP induction (Fig. 2E). BiP increases EnR 
protein folding capacity, contributing to resolution of the stress, and helps reverse UPR 
activation; likely preventing the cytotoxicity that would result if UPR activation was 
sustained. Consistent with its antiapoptotic role, in several cancers, elevated levels of 
BiP are associated with a poor prognosis (9). Estrogen rapidly induced BiP mRNA in 
breast and ovarian cancer cells (Fig. 2F), leading to a 2.3-fold increase in BiP protein 
(Fig. 2G). RNAi knockdown of ER prevented E2-induction of BiP mRNA (Fig. 2H).  
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PERK activation leads to inhibition of protein synthesis (Fig. 1C). Surprisingly, E2 
induces a rapid and transient increase in PERK phosphorylation (Fig. 4A), resulting in 
increased phosphorylation of eIF2 (Fig. 4B) and a modest transient decline in overall 
protein synthesis (Fig. 4C). Consistent with p-PERK catalyzing formation of p-eIF2, 
PERK knockdown inhibited formation of p-eIF2 (Fig. 4D). Consistent with E2 acting 
through ER, ICI inhibited E2-stimulated phosphorylation of PERK and eIF2 and 
largely reversed the E2-mediated inhibition of protein synthesis (Fig. 4A, B, and C). 
PERK activation leads to ATF4 expression, and we observed a transient increase in 
ATF4 expression (Fig. 4E). However, the proapoptotic protein CHOP was not induced 
because mild and transient activation of PERK does not induce CHOP (Fig. 3D, Fig. 4F) 
(35). Together, this data demonstrates that E2, acting through ER, activates all three 
UPR arms. 
 
E2-ER Rapidly Increases Cytosol Ca2+ by a PLC-mediated Opening of the EnR 
IP3R Ca2+ Channel, Activating the UPR 
Rapid UPR activation by E2-ER suggested accumulation of unfolded protein 
was not triggering UPR activation. Some UPR activators, such as thapsigargin, rapidly 
activate the UPR by depleting Ca2+ stores in the lumen of the EnR, increasing 
intracellular Ca2+. To test whether E2 rapidly alters cytosol Ca2+, we monitored cytosol 
calcium using the sensor dye Fluo-4 AM. In the presence or absence of extracellular 
Ca2+, estrogen produced a rapid and transient increase in fluorescence in T47D breast 
cancer cells (Fig. 5A and B). Since E2 increases cytosol Ca2+ when there is no 
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extracellular Ca2+, and the EnR lumen is the major Ca2+ store available to increase 
cytosol Ca2+, E2 is acting by depleting the EnR Ca2+ store. Estrogen also increased 
cytosol calcium in PEO4 ovarian cancer cells (Fig. 6). Inhibition of the IP3R channel with 
2-APB, which locks the IP3R Ca2+ channels closed, and RNAi knockdown of the three 
isoforms of the IP3R channels (Fig. 5C), abolished the rapid E2-ER-mediated increase 
in cytosol Ca2+ (Fig. 5A, B, and D). In contrast, high concentration ryanodine (Ry), which 
closes the ryanodine receptor (RyR) Ca2+ channels, did not block the increase in cytosol 
Ca2+ (Fig. 5A and B). We next assessed whether Ca2+-release was necessary for UPR 
activation using 2-APB and ryanodine individually, or in combination. 2-APB, but not 
ryanodine, inhibited E2-ER activation of the PERK arm of the UPR, as shown by 
inhibition of formation of p-eIF2 (Fig. 7A). RNAi knockdown of IP3R (Fig. 5C) blocked 
E2-induced Ca2+ release (Fig. 5D), activation of the IRE1 arm of the UPR (Fig. 7B), 
and blocked E2-induction of BiP (Fig. 5C), which is a commonly used surrogate readout 
for UPR activation. 
We next tested the possibility that activation of PLC, which hydrolyzes PIP2 to 
DAG and IP3, plays a role in E2-mediated opening of the IP3R Ca2+ channels. Treating 
T47D cells with the PLC inhibitor, U73122, or siRNA knockdown of PLCγ, abolished 
the rapid E2-ER-mediated increase in cytosol Ca2+ (Figure 5E and F; Fig 8). Since 
PLC mediates E2-dependent opening of the IP3R Ca2+ channels and calcium release 
(Fig. 5F), we examined the effect of siRNA knockdown of PLC on E2-ER-dependent 
activation of the UPR. siRNA knockdown of PLC blocked E2-ER activation of the 
ATF6 arm of the UPR, as shown by a reduction in p50-ATF6, and inhibition of BiP 
induction (Fig. 5E).  
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To evaluate the role of ER in the E2-mediated increase in cytosol calcium, we 
performed siRNA knockdown. In T47D cells, RNAi knockdown of ER, in the absence 
of extracellular Ca2+, prevented E2-stimulated calcium release (Figure 5G and H).  PLC 
is on the inner leaflet of the plasma membrane and the E2-ER-mediated increase in 
cytosol Ca2+ occurs in <2 min. Thus, the E2-ER-mediated increase in intracellular Ca2+ 
that leads to UPR activation is a rapid, extranuclear action of ER at the plasma 
membrane. 
 
The UPR and E2-ER Action in E2-ER Stimulated Cell Proliferation 
We explored the role of Ca2+-release from the EnR in promoting E2-ER induced 
gene expression, UPR activation, and subsequent cell proliferation. Consistent with a 
possible role for intracellular Ca2+ in E2-ER action (36), chelating intracellular Ca2+ with 
BAPTA-AM blocked E2-stimulated cell proliferation (Fig. 9A). In T47D cells, PLCy or 
IP3R knockdown, or locking IP3R with 2-APB, strongly inhibited the increase in cytosol 
Ca2+ (Figure 5A, B, D and F), UPR activation (Figure 5C and E, Fig. 7), and E2-ER 
stimulated cell proliferation (Fig. 9A and B). However, IP3R knockdown did not inhibit 
E2-dependent down-regulation of ER or E2-induction of GREB1 or pS2 mRNA (Figure 
9C; Fig. 10B) (37, 38). Similarly, 2-APB did not abolish E2-ER induced expression of 
stably transfected ERE-luciferase in T47D cells, while 2-APB and Ry together, strongly 
inhibited reporter gene expression (Fig. 9D). This suggests there are different 
intracellular Ca2+ requirements for E2-ER-mediated UPR activation and E2-ER-
mediated gene expression. Importantly, the IP3R knockdown data uncouples UPR 
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activation from E2-ER-mediated gene expression, and demonstrates that blocking 
UPR activation is sufficient to inhibit estrogen-stimulated cell proliferation. 
We next evaluated the role of E2-induction of EnR chaperones in E2-ER 
stimulated cell proliferation. Knockdown of PLCy or IP3R strongly inhibited E2-induction 
of BiP and E2-ER stimulated cell proliferation (Fig. 5C and E, Fig. 9A). Knockdown of 
the primary UPR regulator of EnR chaperones, ATF6, also strongly inhibited E2-
induction of BiP and E2-ER stimulated cell proliferation (Fig. 2E and 9A). Thus, UPR 
activation and subsequent induction of EnR chaperones plays an important role in E2-
ER stimulated cell proliferation. 
We further evaluated the effects of PLC, IP3R, ATF6, XBP1, and PERK 
knockdown on E2-stimulated proliferation of MCF-7 cells (Fig. 11). Knockdown of the 
ATF6 and XBP1 arms of the UPR produced 40% declines in E2-stimulated in cell 
proliferation, while PERK knockdown had no effect (Fig. 10E). IP3R knockdown 
produced a 50% decline in E2-ER stimulated MCF-7 cell proliferation (Fig. 9E). This is 
consistent with the 40% decline in proliferation following 2-APB treatment (Fig. 10C), 
which did not fully abolish E2-induction of pS2 and GREB1 mRNA (Fig. 9F; Fig. 10D). 
Targeting IP3R in MCF-7 cells produced less dramatic inhibition of E2-ER stimulated 
cell proliferation compared to T47D cells or BG-1 ovarian cancer cells (Fig. 9A, B, E; 
Fig. 10C and E). Knockdown of PLC in MCF-7 cells nearly abolished E2-ER 
stimulated cell proliferation (Fig. 9E). Together, this data demonstrates that weak 
anticipatory activation of the UPR, resulting in induction of chaperones, plays an 
important role in E2-ER-stimulated cell proliferation. This novel E2-ER pathway 
leading to cancer cell proliferation is shown (Fig. 9G). 
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E2-ER Action Increases Levels of UPR Sensors and Downstream Targets 
We investigated whether E2-ER facilitates UPR activation by inducing the 
sensors that trigger activation of the three UPR arms. E2 rapidly induced mRNAs 
encoding sensors for all 3 UPR arms and the chaperones BiP and GRP94 (Fig. 12A). 
These were early responses, usually visible within 2 hours. Although some responses 
declined at later times, estrogen produced sustained increases in resident chaperones 
and some UPR components, such as eIF2 (Fig. 12A).  
 
E2-ER-regulated Gene Expression and UPR Activation are Correlated In Vivo 
To assess in vivo relevance, we used growing MCF-7 tumors receiving estrogen 
and regressing MCF-7 tumors receiving only cholesterol vehicle (Fig. 12B) and 
compared expression of classical measures of E2-ER activity to markers of UPR 
activation (24). In the +E2 tumors, the markers for E2-ER activity, pS2 and GREB1 
mRNAs (37, 38), were induced 12-fold and 17-fold and all three UPR arms were 
moderately activated (Fig. 12C and D). Consistent with activation of the IRE1 arm of 
the UPR, active sp-XBP1 increased 3-fold while inactive XBP1 declined (Fig. 12D). 
Consistent with E2-activation of the ATF6 arm of the UPR, +E2 tumors displayed 2.0 
and 1.8-fold increases in BiP and GRP94 mRNAs, respectively (Fig. 12D). Levels of 
CHOP and GADD34 mRNA were 2.1-fold and 1.4-fold higher in the +E2 group, 
respectively, indicating weak activation of the PERK arm (Fig. 12D). While levels of 
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primary UPR sensors IRE1 and PERK were reduced in these tamoxifen-sensitive 
tumors, their immediate targets eIF2 and sp-XBP1 were increased (Fig. 12D).  
To assess UPR activity early in ER+ breast cancer development, we compared 
E2-ER activity and UPR pathway activity in samples of histologically normal breast 
epithelium and invasive ductal carcinoma (IDC). Compared to normal epithelium from 
IDC patients, IDC samples displayed elevated levels of ER mRNA and E2-ER 
induced pS2 and GREB1 mRNAs, and reduced levels of E2-ER downregulated IL1-R1 
mRNA (Fig. 12E). IDC samples displayed elevated SERP1 mRNA, a marker for IRE1 
activation (32); CHOP and GADD34, which are markers of PERK activation; and BiP 
and GRP94 chaperones, which are markers of ATF6 activation (Fig. 12F). These data 
suggest UPR activation occurs very early in tumor development. 
Using data from an independent cohort of 278 ER+ breast cancers we explored 
whether expression of ER mRNA and protein, or E2-ER-regulated genes, correlates 
with expression of UPR genes. Expression of several UPR genes displayed highly 
significant correlation with expression of ER and ER-target genes (Table 1).  
 
Prior Estrogen Activation of the UPR Protect Cells from Subsequent Exposure to 
Cell Stress  
     Weakly activating, non-toxic, concentrations of the UPR activator, tunicamcyin 
(TUN), elicit an adaptive stress response that increases EnR chaperones, and renders 
cells resistant to subsequent exposure to an otherwise lethal concentration of 
tunicamycin (35, 39). Consistent with weak E2 activation of the UPR, E2 induces a 2.3-
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fold increase in BiP protein compared to a 5.5-fold increase in BiP following maximal 
UPR activation by a lethal concentration of tunicamycin (Fig. 2G and Fig 13). We tested 
whether prior exposure of T47D cells to E2, or a low concentration of tunicamycin, 
altered the concentration of tunicamycin required to subsequently induce substantial cell 
death. Pre-treating cells with estrogen or TUN had nearly identical effects; each elicited 
an ~10 fold increase in the concentration of tunicamycin required to induce apoptosis 
(Fig. 14A). Thus, the E2-induced weak anticipatory activation of the UPR both facilitates 
tumor cell proliferation and is a potential mechanism by which estrogen might protect 
ER+ breast tumors against subsequent apoptosis due to hypoxia, nutritional 
deprivation and therapy. 
 
A UPR Gene Signature Predicts Clinical Outcome in ER  Positive Breast Cancer  
To explore UPR activation as a potential prognostic marker in ER+ breast 
cancer, we developed a UPR gene signature consisting of genes encoding components 
of the UPR pathway and downstream targets of UPR activation (Table 2). Using data 
from 261 ER+ breast cancer patients, each assigned to a high- or low-genomic UPR 
grade, we observed reduced time to relapse for patients overexpressing the UPR 
signature (hazard ratio (HR) = 5.5, 95% CI: 3.1-9.8) (Fig. 15A and B). To evaluate the 
UPR signature in patients undergoing tamoxifen therapy, samples collected from 474 
ER+ breast cancer patients, prior to starting 5-years of tamoxifen therapy, were 
assigned to low, medium, or high UPR risk groups. Increased prior expression of the 
UPR gene signature was tightly correlated with subsequent reduced time to recurrence 
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(Figure 14B and D; Fig. 15C). Hazard ratios increased from 2.2 to 3.7 for the medium 
and high-risk groups, respectively, suggesting that recurrence risk is sensitive to levels 
of the UPR gene signature (Fig. 14B). The UPR index provides prognostic information 
beyond current clinical covariates. In a cohort of 236 ER+ breast cancer patients, UPR 
overexpression was strongly predictive of reduced survival (HR 2.69, 95% CI: 1.3-5.6), 
over and above clinical covariates alone (tumor grade, node involvement, tumor size 
and ER status) (Fig. 14C and D; Fig. 15D). Thus, the UPR index is a powerful 
prognostic gene signature in ER+ breast cancer with predictive power to stratify 
patients into high and low risk groups. 
 
Discussion 
In contrast to the well-studied “reactive mode” of UPR activation that occurs in 
response to endoplasmic reticulum stress, there are few studies of UPR activation that 
anticipates the future need for increased capacity to fold and sort proteins, and occurs 
in the absence of endoplasmic reticulum stress (7). Anticipatory UPR activation is 
observed in B-cell differentiation where UPR activation in plasma cells precedes the 
massive production and secretion of immunoglobulins (13, 14). Because the signals 
responsible for anticipatory activation of the UPR are largely unknown, it is poorly 
understood.  
In the absence of cell stress or misfolded proteins, the mitogen, estrogen, acting 
via ER, triggers anticipatory activation of the UPR in breast and ovarian cancer cells. 
In less than 2 minutes, E2-ER triggers PLC-mediated opening of EnR IP3R calcium 
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channels and release of Ca2+ into the cytosol. This increase in cytosol Ca2+ stimulates 
activation of all three arms of the UPR and is required for E2-ER-stimulated cell 
proliferation.   
Anticipatory activation of the UPR by E2-ER enhances EnR protein folding 
capacity, and thereby primes cells to meet the higher protein folding and sorting 
demands that characterize the later growth phases of the cell cycle. The major EnR 
chaperone BiP, plays a central role in EnR homeostasis, protein processing, and UPR 
signaling. Since BiP knockdown stimulates UPR activation and promotes EnR stress-
induced apoptosis (10, 40), and cells undergoing E2-mediated apoptosis have lower 
levels of chaperones (41), we assessed the consequences of abrogating the expansion 
of EnR protein-folding capacity by blocking anticipatory activation of the UPR. PLC, 
IP3R or ATF6 knockdown blocked E2-induction of BiP and inhibited E2-ER stimulated 
proliferation of T47D cells. While IP3R knockdown nearly abolished E2-ER-stimulated 
Ca2+-release from the EnR, and this blocked UPR activation, it did not inhibit E2-ER-
mediated gene expression. Thus, inhibition of E2-ER-stimulated UPR activation and 
chaperone induction is sufficient to inhibit E2-ER stimulated cell proliferation. Using 2-
APB and ryanodine together, or chelating intracellular calcium with BAPTA, completely 
abrogated the increase in intracellular calcium, and blocked E2-ER-regulated gene 
expression. Based on the inhibitor and knockdown data, we hypothesize that very small 
increases in intracellular calcium are sufficient to enable E2-ER-regulated gene 
expression and that somewhat larger increases in intracellular calcium are likely 
required for E2-ER activation of the UPR. E2-ER induces a substantial increase in 
intracellular calcium, which may promote coordination between the nucleus and 
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endoplasmic reticulum, and couple activation of the E2-ER genomic program with UPR 
activation and expansion of the EnR protein-folding capacity. 
We further validated the importance of this novel extranuclear pathway of E2-
ER action using MCF-7 cells to assess how knockdown of each pathway component 
affects E2-ER stimulated cell proliferation. PERK knockdown produced a 20% in E2-
ER-stimulated cell proliferation, and may be required to fully activate the ATF6 arm of 
the UPR (42). Knockdown of the XBP1 or ATF6 produced a 40% decline in E2-ER-
stimulated cell proliferation. IP3R knockdown produced an even larger reduction in E2-
ER stimulated cell proliferation, while PLC knockdown had the largest effect. Thus, 
anticipatory activation of the UPR plays an important role in E2-ER dependent 
proliferation of cancer cells.  
As expected (1, 3), IDC tumor samples exhibited increased ER expression and 
activation compared to normal breast epithelial tissue. Consistent with a role for the 
UPR in this proliferative phase of early tumor development, increased UPR expression 
and activation was observed in IDC tumor samples. This suggests that increased UPR 
expression occurs early in tumor development, long before detection, diagnosis, and the 
initiation of treatment.  
Activation of the UPR by E2-ER exerts a long-term impact on the pathology of 
ER positive breast cancer. Weak activation of the UPR by estrogen, or by tunicamcyin, 
elicits an adaptive response that protects cells from subsequent exposure to higher 
levels of cell stress. We explored whether the effects of E2-ER on the UPR correlated 
with clinical resistance to tamoxifen therapy. Increased UPR activation and elevated 
expression of UPR components were predictive of a poor response to tamoxifen-
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therapy, shorter time to recurrence, and decreased overall survival. If UPR expression 
promotes resistance to tamoxifen therapy, some UPR genes should exhibit differential 
regulation in our tamoxifen-sensitive MCF-7 tumors (24), compared to their expression 
in the tamoxifen-resistance gene signature. Supporting this view, several genes 
encoding UPR components were E2-downregulated in tamoxifen-sensitive MCF-7 
tumors, but elevated in the human tumors expressing the tamoxifen-resistance gene 
signature (PERK, p58IPK). 
For ER+ breast cancers resistant to endocrine therapies, an important objective 
is development of more specific biomarkers that predict therapeutic response and 
identification of new therapeutic targets. The UPR is a new biomarker and therapeutic 
target in ER+ breast cancer; validated through mechanistic studies in culture, a mouse 
xenograft, and bioinformatics analysis of patient tumor samples. Anticipatory estrogen 
activation of the UPR is a novel extranuclear action of ER, a previously undescribed 
early component of the estrogen-ER cell proliferation program and a new paradigm by 
which estrogens may influence tumor development and resistance to therapy. 
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Figure 3.1. Endoplasmic reticulum (EnR) stress activates the three arms of the 
UPR. (A) EnR stress induces the oligomerization, autophosphorylation, and activation 
of the transmembrane endoribonuclease, IRE1. Activated IRE1 removes an intron 
from full-length XBP1 (fl-XBP1) mRNA, producing spliced-XBP1 (sp-XBP1) mRNA, 
which is subsequently translated into active sp-XBP1 protein. sp-XBP1 enhances the 
protein-folding capacity of the EnR, increases turnover of misfolded proteins by inducing 
EnR-associated degradation (ERAD) genes, and alters mRNA decay and translation (6, 
7). ERDJ and SERP1 are commonly used readouts of IRE1 activation (32, 43, 44). (B) 
EnR stress activates the transmembrane protein, activating transcription factor 6  
(ATF6). Full-length ATF6 (p90-ATF6) translocates from the EnR to the Golgi 
Apparatus, where it is cleaved by site-1 and site-2 proteases, resulting in the release of 
a 50-kDa ATF6 (p50-ATF6) fragment into the cytosol. p50-ATF6 enters the nucleus 
and induces several UPR genes including BiP, GRP94, calreticulin, and other EnR 
chaperones (34). (C) EnR stress induces the oligomerization, autophosphorylation, and 
activation of the transmembrane kinase PERK (6, 7). P-PERK phosphorylates 
eukaryotic initiation factor 2 (eIF2), leading to general inhibition of protein synthesis 
and a reduction in the endoplasmic reticulum protein folding load. However, increased 
eIF2 phosphorylation also leads to preferential translation of certain mRNA, including 
the transcription factor, ATF4 (6, 7). Increased translation of ATF4 induces the 
transcription factor CHOP, which induces GADD34 and several pro-apoptotic genes. 
Inhibition of protein synthesis is normally reversed by inactivating PERK and 
dephosphorylating eIF2. p58IPK binds PERK, inhibiting PERK activation, and GADD34 
forms a phosphatase complex with protein phosphatase 1 (PP1), which 
dephosphorylates eIF2 (45-47). 
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Figure 3.2. E2-ER activates the IRE1 and ATF6 arms of the UPR in breast and 
ovarian cancer cells, resulting in the induction of the major EnR chaperone, BiP. 
(A) qRT-PCR comparing the effect of estrogen (E2), ICI 182,780 (ICI) and 4-
hydroxytamoxifen (4-OHT) on E2-ER induction of spliced-XBP1 (sp-XBP1) in T47D 
breast cancer cells (n = 3; -E2 set to 1). Different letters indicate a significant difference 
among groups (p < 0.05) using one-way ANOVA followed by Tukey’s post hoc test. (B) 
qRT-PCR showing the effect of E2-ER on sp-XBP1 mRNA in MCF-7 breast and PEO4 
ovarian cancer cells (n = 3; -E2 set to 1). P-values testing for significance between 
indicated group and -E2 group. (C) RNAi knockdown of ER abolishes E2-induction of 
sp-XBP1 in MCF-7 cells (n = 3). Cells treated with 100 nM non-coding control (NC) or 
ER siRNA SmartPools for 3 days, followed by E2 treatment for the indicated times (D) 
Western blot analysis showing full-length 90 kDa ATF6 (p90-ATF6) and 
proteolytically cleaved 50 kDa ATF6 (p50-ATF6) in E2-treated T47D breast cancer 
cells. (E) RNAi knockdown of ATF6 blocks E2-induction of BiP in T47D cells. Cells 
treated with 100 nM non-coding control (NC) or ATF6 siRNA SmartPool for 3 days, 
followed by E2 treatment for 4 hours. (F) qRT-PCR showing the effect of E2 on BiP 
mRNA in MCF-7 cells and in PEO4 ovarian cancer cells (n = 3; -E2 set to 1). (G) 
Western blot analysis of BiP protein levels in MCF-7 cells treated with E2. The fold-
change in BiP protein levels is shown below each lane and was determined by 
quantifying BiP and β-Actin signals, and calculating the ratio of BiP/β-Actin (t=0, [-E2], 
set to 1). (H) RNAi knockdown of ER abolishes E2-induction of BiP in MCF-7 cells (n = 
3). Cells treated with 100 nM non-coding control (NC) or ER siRNA SmartPools for 3 
days, followed by E2 treatment for the indicated times. Concentrations: E2, 1 nM (A, D), 
10 nM (B, C, E-H); ICI, 1 μM (A, D); 4-OHT, 1 μM (A). Data is mean ± S.E.M. * p < 0.05; 
** p < 0.01; *** p < 0.001. 
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Figure 3.3. E2-ER induces the UPR. (A) E2-ER stimulates induction of downstream 
transcriptional targets of spliced-XBP1, SERP1 and ERDJ.(32, 43, 44) The increase in 
SERP1 and ERDJ mRNA coincides with increased splicing of XBP1 mRNA, which 
together indicate that E2-ER stimulates activation of the IRE1-arm of the UPR. -E2 
treatment set to 1. P-values testing for significance between indicated group and -E2 
group. (B) ER knockdown abolishes E2-induction of GREB1 (growth regulated by 
estrogen in breast cancer 1) mRNA, which is a well-established transcriptional target of 
E2-ER (38, 48). (C) E2-ER activates the ATF6 arm of the UPR in PEO4 ovarian 
cancer cells. The increase in the level of p50-ATF6 (p50-ATF6) demonstrates 
activation of the ATF6 arm of the UPR. Ug-ATF6 band represents the unglycosylated 
or underglyosylated precursor of p90-ATF6, which has been described previously (49). 
(D) qRT-pCR analysis of CHOP mRNA following treatment of MCF-7 cells with E2, or 
the UPR activator tunicamycin (TUN). Concentrations: E2, 10 nM; TUN, 10 μg/mL. Data 
is mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; ns, not significant. 
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Figure 3.4. E2-ER activates the PERK arm of the UPR. Western blot analysis 
showing (A) p-PERK and total PERK levels and (B) p-eIF2 levels and total eIF2 
levels in T47D cells treated with ICI 182,780 (ICI) or a vehicle control for 2 hours, 
followed by treatment with 10 nM 17-estradiol (E2) (n = 3). Numbers below each lane 
are the ratio of p-PERK/PERK or p-eIF2/eIF2 normalized to the vehicle-treated 
control. (C) Protein synthesis in ER+ T47D breast cancer cells treated with ICI 182,780 
(ICI) or a vehicle control for 2 hours, followed by treatment with 10 nM 17-estradiol 
(E2) (n = 3). P-values testing for significance between indicated groups and -E2 
samples. (D) PERK knockdown inhibits downstream phosphorylation of eIF2 in T47D 
cells. (E) Western blot analysis of ATF4 following treatment of T47D cells with E2, or the 
UPR activator tunicamycin (TUN). (F) qRT-pCR analysis of CHOP mRNA following 
treatment of T47D cells with E2. Brackets denote pre-treatment with ICI for 2 hours. 
Concentrations: E2, 1 nM (A-F); ICI, 1 μM (A, B, C); TUN, 10 μg/mL (E). Data is mean ± 
SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.  
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Figure 3.5. Estrogen stimulates the release of calcium from the endoplasmic 
reticulum, and this calcium release is necessary for UPR activation. (A) Effects of 
300 nM estrogen (E2) on cytosolic calcium levels in T47D breast cancer cells 
conditioned in the presence (2 mM CaCl2) or absence (0 mM CaCl2) of extracellular 
calcium, or cells pre-treated with 2-APB or ryanodine (Ry) for 30 minutes in the absence 
of extracellular calcium (0 mM CaCl2). Visualization of intracellular Ca2+ using Fluo-4 
AM. Colors from basal Ca2+ to highest Ca2+: Blue, green, red, white. (B) Graph depicts 
quantitation of cytosolic calcium levels in ER+ T47D breast cancer cells treated with E2 
in the presence or absence of extracellular calcium, and in cells pre-treated with 2-APB 
or ryanodine (Ry) in the absence of extracellular calcium (n = 10 cells). E2 was added at 
60 sec, and fluorescence intensity prior to 60 sec was set to 1. (C) Western blot 
analysis of IP3R and BiP protein levels following treatment of T47D cells with either 100 
nM non-coding (NC) siRNA or a IP3R SmartPool, followed by treatment with E2 (+E2) or 
ethanol-vehicle (-E2) for 4 hours. IP3R smartpool contained 33 nM siRNA directed 
against each isoform of IP3R Ca2+-channel. (D) Quantitation of cytosolic Ca2+ levels in 
response to E2, following treatment of T47D cells with 100 nM non-coding (NC) siRNA 
or IP3R siRNA SmartPools for 3 days (n = 10 cells) (E) Western blot analysis of PLC, 
BiP, and ATF6 protein levels after treatment of T47D cells with 100 nM non-coding 
(NC) siRNA or PLC siRNA SmartPool, followed by treatment with E2 (+E2) or ethanol-
vehicle (-E2) for 4 hours. (F) Quantitation of cytosolic Ca2+ levels in response to E2, 
following treatment of T47D cells with 100 nM non-coding (NC) siRNA or PLC siRNA 
SmartPool for 3 days. (G) Western blot analysis of ER protein levels after treating 
T47D cells with either 100 nM non-coding (NC) siRNA or ER siRNA SmartPool, 
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followed by treatment with E2 (+E2) or ethanol-vehicle (-E2) for 4 hours. (H) 
Visualization and quantitation of cytosolic Ca2+ levels in response to E2 after ER 
knockdown in T47D cells. Concentrations: E2, 300 nM (A, B, D, F, H), 1 nM (C, E, G); 2-
APB, 200 M (A, B); ryanodine, 200 M (A, B). Graphical data is mean ± SE (n = 10). 
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Figure 3.6. Estrogen increases intracellular calcium levels in ER+ PEO4 ovarian 
cancer cells. Effect of 300 nM E2 on intracellular calcium levels in ER+ PEO4 ovarian 
cells. Cells visualized with the Ca2+ sensitive dye Fluor-4. Low levels of basal [Ca2+] are 
blue and then green, whereas higher levels of [Ca2+] are seen as red, with the highest 
levels white. The trace represents relative signal intensity averaged from 10 cells. E2 
was added at 60 sec, and fluorescence intensity prior to 60 sec was set to 1. Data is 
mean ± S.E. 
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Figure 3.7. Blocking Ca2+-release from the EnR through the IP3R Ca2+ channel 
prevents estrogen-dependent activation of the IRE1 and PERK arms of the UPR. 
(A) Pre-blocking the IP3R Ca2+-channel with 2-APB prevents estrogen-dependent 
activation of the PERK arm of the UPR in T47D cells. Western blot analysis showing p-
eIF2 and total eIF2 levels in T47D breast cancer cells pre-treated for 30 minutes with 
2-APB and/or ryanodine (Ry) or a vehicle control, followed by treatment with E2 for 30 
minutes. Numbers below each lane are the ratio of p-eIF2/eIF2 with the vehicle-
treated control set at 100. (B) IP3R knockdown abolishes E2-induction of sp-XBP1 
mRNA in T47D cells. Cells were treated with non-coding control (NC) or IP3R siRNA 
SmartPools for 3 days, followed by E2 treatment for 4 hours. Data is mean ± SEM. 
Letters indicate a significant difference among groups (p < 0.05) using one-way ANOVA 
followed by Tukey’s post hoc test. Concentrations: E2, 10 nM; 2-APB, 200 M; 
Ryanodine, 200 M. 
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Figure 3.8. Treatment of T47D cells with the PLCγ inhibitor, U73122, blocks E2-
stimulated calcium release. Graph depicts quantitation of cytosolic calcium levels in 
ER+ T47D breast cancer cells pre-treated with DMSO vehicle or U73122, followed by 
treatment with 300 nM E2 in the absence of extracellular calcium (n = 10 cells). E2 was 
added at 60 sec, and fluorescence intensity prior to 60 sec was set to 1. Data is mean ± 
S.E. 
 
 
 
  
87 
 
 
 
 
Figure 3.9. E2-ER induced calcium release from the EnR into the cytosol is 
important for E2-ER mediated gene expression and E2-ER stimulated cell 
proliferation. (A) E2-ER stimulated proliferation of T47D breast cancer cells treated 
100 nM non-coding (NC), PLC, IP3R, or ATF6 siRNA SmartPools (n = 6). (B) E2-ER 
stimulated proliferation of T47D breast cancer cells treated with ryanodine (Ry), 2-APB, 
or both inhibitors (Ry + 2-APB) for 4 days (n = 5). (C) qRT-PCR analysis of effects of 
IP3R knockdown on E2-ER induction of GREB1 mRNA in T47D cells (n = 3). Western 
blot shows ER protein levels after treatment of T47D cells with 100 nM non-coding 
(NC) siRNA or IP3R siRNA, followed by treatment with E2 (+E2) or ethanol-vehicle (-E2) 
for 4 hours. (D) ERE-luciferase activity in kBluc-T47D breast cancer cells treated with E2 
and either ryanodine (Ry), 2-APB, or both inhibitors for 24-hours (Ry + 2-APB) (n = 4). 
(E) E2-ER stimulated proliferation of MCF-7 breast cancer cells treated 100 nM non-
coding (NC), PLC, IP3R, ATF6, XBP1, or PERK siRNA (n = 6). (F) qRT-PCR analysis 
of effects of ryanodine (Ry), 2-APB, or both inhibitors (Ry + 2-APB) on E2-ER induction 
of pS2 mRNA in MCF-7 cells (n = 3). (G) Model of E2-ER acting through the UPR to 
influence breast tumorigenesis. “•” denotes cell number at day 0. Concentrations: E2, 
100 pM (A-F); 2-APB, 200 M (B, D, F); Ryanodine, 100 M (B, D, F). Data is mean ± 
SEM. Different letters indicate a significant difference among groups (p < 0.05) using 
one-way ANOVA followed by Tukey’s post hoc test. ns, not significant (p > 0.05).  
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Figure 3.10. E2-ER induced calcium release from the EnR into the cytosol is 
important for E2-ER mediated gene expression and E2-ER stimulated cell 
proliferation. (A) Effects of the intracellular calcium chelator BAPTA-AM on E2-ER 
stimulated cell proliferation (n = 5). MCF-7 cells were treated with 10 M BAPTA-AM for 
3 days. (B) qRT-PCR analysis of effects of IP3R knockdown on E2-ER induction of pS2 
mRNA in T47D cells (n = 3). (C) E2-ER stimulated proliferation of MCF-7 breast cancer 
cells treated with ryanodine (Ry), 2-APB, or both inhibitors (Ry + 2-APB) for 4 days (n = 
5). (D) qRT-PCR analysis of effects of ryanodine (Ry), 2-APB, or both inhibitors (Ry + 2-
APB) on E2-ER induction of GREB1 mRNA in MCF-7 cells (n = 3). (E) E2-ER 
stimulated proliferation of BG-1 ovarian cancer cells treated with ryanodine (Ry), 2-APB, 
or both inhibitors (Ry + 2-APB) for 4 days (n = 5). “•” denotes cell number at day 0. Data 
is mean ± SEM. Letters indicate a significant difference among groups (p < 0.05) using 
one-way ANOVA followed by Tukey’s post hoc test. * P < 0.05; ** P < 0.01; *** P < 
0.001; ns, not significant. Concentrations: E2, 100 pM; 2-APB, 200 M; Ryanodine, 200 
M. 
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Figure 3.11. Western blot analysis of UPR proteins following siRNA knockdown in 
MCF-7 cells. Western blot analysis of (A) PLC, (B) pan-IP3R, (C) ATF6, (D) XBP1, 
and (E) PERK protein levels following treatment of MCF-7 cells with either 100 nM non-
coding SmartPool siRNA or 100 nM SmartPool siRNA directed against the protein of 
interest. The IP3R SmartPool consisted of three individual siRNAs SmartPools targeting 
each isoform of the IP3R Ca2+-channel (ITPR1, ITPR2, ITPR3).  
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Figure 3.12. E2-ER activity and UPR activity are correlated in vivo. (A) qRT-PCR 
analysis of levels of mRNAs for each arm of the UPR after treatment of MCF-7 cells 
with 10 nM E2 for the indication times (n = 3). (B) MCF-7 tumor growth in the presence 
or absence of estrogen in athymic mice. All mice were treated with estrogen to induce 
tumor formation. On “Day 0”, E2 in silastic tubes was replaced with silastic tubes 
containing only cholesterol in the –E2 group (n = 15), while silastic tubes were retained 
in the +E2 treatment group (n = 15). qRT-PCR analysis of (C) classical E2-ER 
regulated genes and (D) the UPR in mouse tumors collected after 24 days of exposure 
to estrogen (+E2) or vehicle-control (-E2) (n = 15). Relative mRNA levels of (E) classical 
E2-ER regulated genes and (F) the UPR pathway in patient samples of normal breast 
epithelium taken from patients undergoing reduction mammoplasty (RM) (n = 18), 
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histologically normal breast epithelium taken from patients diagnosed with invasive 
ductal carcinoma (IDC) (n = 9), and carcinoma epithelium taken from IDC patients (n = 
20). p-values represent comparisons to –E2 groups (A, C, D) or to histologically normal 
breast epithelium from patients who underwent reduction mammoplasty (e, f). Data is 
mean ± SEM. * P < 0.05; ** P < 0.01; ***P < 0.001; ns, not significant. 
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Figure 3.13 The UPR Activator, tunicamycin, induces BiP. Time course analysis of 
BiP protein levels following tunicamycin (TUN) treatment. Densiometric analysis 
performed by normalizing BiP protein levels to -Actin. 
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Figure 3.14. Anticipatory activation of the UPR by estrogen protects cells from 
subsequent cell stress, and expression of the UPR gene signature predicts 
relapse-free and overall survival in ER positive breast tumor cohorts. (A) Weak 
anticipatory activation of the UPR with estrogen or tunicamycin protects cells from 
subsequent UPR stress. T47D cells were maintained in 10% CD-FBS for 8 days and 
treated with either 250 ng/ml tunicamycin (TUN), 100 pM E2, or ethanol/DMSO-vehicle 
(Untreated). E2, TUN, or the vehicle control were removed from medium, and cells were 
harvested in 10% CD-calf serum and treated with the indicated concentrations of 
tunicamycin. Data is mean ± SEM (n = 6). Different letters indicate a significant 
difference among groups (p < 0.05) using one-way ANOVA followed by Fisher’s LSD 
post hoc test. (B) Relapse-free survival as a function of the UPR gene signature for 
patients with ER+ breast cancer who subsequently received tamoxifen alone for 5 
years. Interquartile range used to assign tumors to risk groups, representing UPR 
activity from high to low. Hazard ratios are between low and medium and low and high 
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UPR groups (n = 474). (C) Overall survival as a function of the UPR signature and 
clinical covariates (node status, tumor grade, ER-status, tumor size). p-value is testing 
for significance between the combined model (UPR gene signature and clinical 
covariates) versus the covariates only model (multivariate analysis) (n = 236). (D) 
Univariate and multivariate Cox regression analysis of the UPR signature, clinical 
covariates, and classical estrogen-induced genes for time to recurrence and survival 
(n.s., not significant). Median used to classify tumors into high and low risk groups. 
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Figure 3.15. The UPR genomic index is a new biomarker that predicts relapse free 
and overall survival of breast cancer patients. (A) Relapse rate of 261 ER positive 
breast tumors, classified by expression levels of the UPR gene signature, plotted by the 
Kaplan-Meier method. Tumor samples were analyzed on both, U133A and U133B gene 
chips. The table below denotes univariate and multivariate Cox regression hazard ratios 
and p-values for the UPR gene signature and other clinical covariates (tumor grade, 
tumor size, node status). (B) UPR genes independently predictive of relapse (p < 0.05) 
in gene expression profiles obtained from 277 ER+ positive breast cancers (27). 
Kaplan-Meier plots and Cox regression hazard analysis for this tumor cohort is 
displayed in Figure 15A. (C) UPR genes independently predictive of relapse in 474 
gene expression microarrays taken from ER-positive breast cancer patients prior to 
the initiation of tamoxifen-therapy (27, 28). Kaplan-Meier analysis and Cox regression 
hazard analysis for this tumor cohort are displayed in Figure 14B and Figure 14D, 
respectively. (D) UPR genes predictive of survival in 236 gene expression microarrays 
from breast cancer patients (29). Kaplan-Meier plots and Cox regression hazard 
analysis for this tumor cohort is displayed in Figure 14C and Figure 14D, respectively. 
All Kaplan-Meier plots assessing UPR risk prediction were computed using leave-one-
out cross-validation. UPR signature genes shown in the tables are listed with their 
respective univariate Cox hazard ratio and p-value test the hypothesis if expression 
data is predictive of relapse or overall survival. 
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Table 3.1. Expression of UPR genes is positively correlated with expression of 
ER and ER-regulated target-genes. Correlations between the UPR and ER 
protein levels (ER), ER mRNA levels (ESR1), or transcriptional activity of E2-ER. 
E2-ER transcriptional activity was assessed using downstream target genes of E2-ER 
(pS2, GREB1) (38, 48, 50). Analysis carried out on a cohort of 278 breast cancer 
patients (GSE20194) (26), which consisted of 164 ER positive tumors and 114 ER 
negative tumors. Quantitation of ER protein was by IHC. Pearson correlation 
coefficients and parametric p-values are shown in the table. “n.s.” indicates that no 
significant correlation was observed. While expression of UPR genes is correlated with 
ER levels and expression of ER-regulated genes, the UPR index is not simply a 
surrogate marker for ER activity. In multivariate analysis, the UPR index, but not ER, 
or classical ER-regulated genes, exhibits a statistically significant increase in hazard 
ratio (Fig. 14D). Also, UPR index exhibits predictive power to stratify patients into high 
and low risk groups above ER status (Fig. 14C). Thus, while active ER is important 
for expression of the UPR signature, it’s the UPR signature not ER level or activity that 
is predictive of reduced time to recurrence and reduced survival. 
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Table 3.2. UPR gene signature. The table shows the genes used to construct the UPR 
gene signature. HUGO Gene Nomenclature Committee (HGNC) approved names for 
each gene are shown in parenthesis. UPR genes independently predictive either of 
relapse free or overall survival (p < 0.05) were used to construct the UPR gene 
signature, which was then used to carry out risk prediction analysis. 
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CHAPTER 4 
AN ESTROGEN RECEPTOR  INHIBITOR ACTIVATES THE 
UNFOLDED PROTEIN RESPONSE, BLOCKS PROTEIN SYNTHESIS 
AND INDUCES TUMOR REGRESSION 
 
Abstract 
Recurrent estrogen receptor  (ER) positive breast and ovarian cancers are 
often therapy-resistant. Using screening and functional validation, we identified BHPI, a 
potent non-competitive small molecule ER biomodulator that selectively blocks 
proliferation of drug-resistant ER positive breast and ovarian cancer cells. In a mouse 
xenograft model of breast cancer, BHPI induced rapid and substantial tumor regression. 
While BHPI potently inhibits nuclear estrogen-ER-regulated gene expression, BHPI is 
effective because it elicits sustained ER-dependent activation of the endoplasmic 
reticulum (EnR) stress sensor, the unfolded protein response (UPR) and persistent 
inhibition of protein synthesis. BHPI distorts a newly described action of estrogen-ER, 
mild and transient UPR activation. In contrast, BHPI elicits massive and sustained UPR 
activation, converting the UPR from protective to toxic. In ER+ cancer cells, BHPI 
rapidly hyperactivates plasma membrane PLC, generating IP3, which opens EnR IP3R 
calcium channels, rapidly depleting EnR Ca2+ stores. This leads to activation of all three 
arms of the UPR. Activation of the PERK arm, stimulates phosphorylation of eukaryotic 
initiation factor 2 (eIF2), resulting in rapid inhibition of protein synthesis. The cell 
attempts to restore EnR Ca2+ levels, but the open EnR IP3R calcium channel leads to an 
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ATP-depleting futile cycle, resulting in activation of the energy sensor AMPK and 
phosphorylation of eukaryotic elongation factor 2 (eEF2). eEF2 phosphorylation inhibits 
protein synthesis at a second site. BHPI’s novel mode of action, high potency, and 
effectiveness in therapy-resistant tumor cells, make it an exceptional candidate for 
further mechanistic and therapeutic exploration. 
Introduction 
Estrogens, acting via estrogen receptor  (ER), stimulate tumor growth (1-3). 
Approximately 70% of breast cancers are ER positive and most deaths due to breast 
cancer are in patients with ER+ tumors (2, 4). Endocrine therapy using aromatase 
inhibitors to block estrogen production, or tamoxifen and other competitor antiestrogens, 
often results in selection and outgrowth of resistant tumors.  Epithelial ovarian cancer 
usually presents at an advanced stage (5). Although 30-70% of these tumors are ER 
positive (1), endocrine therapy is largely ineffective (6-8). After several cycles of 
combination chemotherapy using taxanes and platinum, tumors recur as resistant 
ovarian cancer (5). More than half of ovarian cancer patients die within 5 years (9). 
Non-competitive ER inhibitors targeting this unmet therapeutic need including 
DIBA, TPBM, TPSF, and newly described LRH-1 inhibitors that reduce ER levels, 
show limited specificity, require high concentrations (>5 M) and have usually not 
advanced through preclinical development (10-13). These non-competitive ER 
inhibitors and competitor antiestrogens are primarily cytostatic and act by preventing 
estrogen-ER action; therefore, they are largely ineffective in therapy-resistant ER 
containing cancer cells that no longer require estrogens and ER for growth. 
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To target the estrogen-ER axis in therapy-resistant cancer cells, we developed 
(14) and implemented an unbiased pathway-directed screen of ~150,000 small 
molecules. We identified ~2,000 small molecule biomodulators of 17-estradiol (E2)-
ER induced gene expression, evaluated these biomodulators for inhibition of E2-ER-
induced cell proliferation and performed simple follow-on assays to identify inhibitors 
with a novel mode of action. Here, we describe BHPI, our most promising small 
molecule ER biomodulator. BHPI non-competitively interacts with ER, resulting in two 
independent effects: Sustained inhibition of protein synthesis that blocks growth and 
ultimately kills many ER+ breast, ovarian and endometrial cancer cells and rapid 
suppression of E2-ER-regulated gene expression. 
In response to stress cancer cells often activate the endoplasmic reticulum (EnR) 
stress sensor, the unfolded protein response (UPR). We recently showed that as an 
essential component of the E2-ER proliferation program, estrogen induces a different 
mode of UPR activation, a weak anticipatory activation of the UPR prior to increased 
protein folding loads that accompany cell proliferation. This weak and transient E2-ER-
mediated UPR activation is protective (15). BHPI distorts this normal action of E2-ER 
and induces a massive and sustained ER-dependent activation of the UPR, converting 
UPR activation from cytoprotective to cytotoxic.  
 
Materials and Methods 
Cell Culture and Reagents  
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 MCF-7, T47D, T47D-kBluc, HCC-1500, ZR-75-1, MCF10A, MDA MB-231, CAOV-
3, OVCAR-3, IGROV-1, ES2, ECC-1, HeLa, PC-3, DU145, H1793, A549, MEF, and 
HepG2 cells were obtained from the ATCC. Dr. E. Wilson provided HeLa-AR13 cells, 
Dr. K. Korach provided BG-1/MCF-7 cells, Dr. B.H. Park provided MCF10AER IN9 cells, 
Dr. R. Schiff provided BT-474 cells, and E. Alarid provided MCF7ERHA cells. Prior to 
experiments, to deplete cells of estrogens in the serum and medium, ER positive cell 
lines were maintained for 4 days in medium supplemented with phenol red-free 
charcoal-dextran (CD) treated serum. 
 
Chemical Libraries and Screening  
The small molecule libraries screened were: The ~150,000 small molecule 
Chembridge MicroFormat small molecule library, the ~10,000 small molecule University 
of Illinois Marvel library developed by Drs. K. Putt and P. Hergenrother (16), and the 
~2,000 small molecule NCI diversity set obtained from NIH. High throughput screening 
for small molecule inhibitors of endogenous E2-ER induced expression of the stably 
transfected (ERE)3-luciferase reporter in T47D-KBluc cells, was carried out using the 
assay we recently described (14). 
 
Cell Proliferation Assays 
Cells were resuspended in the following media and plated in 96 well plates at the 
indicated densities: MCF-7 (10% CD-calf, 1,000 cells); MCF7ERHA (10% CD-calf, 
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1,000); T47D (10% CD-calf, 2,000); T47D- kBluc (10% CD-FBS, 1,000); HCC-1500 
(10% CD-FBS, 1,000); BT-474 (10% CD-calf, 2,000); ZR-75-1 (10% CD-calf 2,000); 
MCF10AER IN9 (2% CD-FBS, 1,000); MCF10A (2% CD-FBS, 1,000); MDA MB-231 (10% 
FBS, 1,000); BG-1 (5% FBS, 250); CaOV-3 (10% CD-CALF, 2,000); OVCAR-3 (10% 
CD-FBS, 2,000); IGROV-1 (10% FBS, 1,000); ES2 (10% FBS, 1,000); ECC-1 (5% CD-
FBS, 1,000); Ishikawa (10% CD-calf, 2,000); HeLa (10% FBS, 1,000); PC-3 (10% CD-
FBS, 1,000); DU145 (10% FBS, 1,000); 201T (10% FBS, 2,000); 273T (10% FBS, 
1,000); H1793 (5% FBS, 2,000); A549 (10% FBS, 1,000); HepG2 (10% CD-FBS, 
1,000), MEF (10% FBS, 2,000). The medium was replaced with treatment medium the 
following day, and plates were incubated at 37o C in 5% CO2 for 4 days except for BT-
474, BG-1/MCF-7 and Ishikawa which were incubated for 6 days and ZR-75-1 cells 
which were incubated for 7 days. Treatment solutions were replaced every two days. 
Cell number was determined from MTS assays using CellTiter 96 Aqueous One 
Solution Reagent (Promega). For each cell line, cell number was calculated from a 
standard curve of the number of plated cells versus A490.  
 
ATP Measurements 
To measure ATP levels, cells were lysed and ATP luminescence levels were 
measured using an ATPlite Luminesence Assay kit (PerkinElmer, MA). ATP released 
from cells was quantified from a standard curve of ATP standards versus luminescence. 
 
Luciferase Assays 
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Reporter gene assays were carried out, as previously described (14, 17). Briefly, 
cells were switched to 10% CD-FBS for four days prior to experiments, and plated at a 
density of 50,000 cells/well in 24-well plates. The medium was replaced the next day 
with medium containing the test compounds, with or without hormone, incubated for 24 
hours and luciferase assays were performed using Bright Glow reagent (Promega, WI). 
 
qRT-PCR  
RNA was extracted using a QiaShredder kit (Qiagen) for cell homogenization, 
and purified with the RNAeasy mini-kit (Qiagen, CA). cDNA was prepared from 0.5 g of 
RNA by reverse transcription using a DyNAmo cDNA synthesis kit (Finnzymes, 
Finland). Quantitative PCR assays were performed on samples from 3 independent sets 
of cells (biological triplicate). Reactions contained 10 ng of cDNA and 50 nM forward 
and reverse primers in 15 l and were carried out using Power SYBR Green PCR 
Mastermix (Applied Biosystems). The fold change in expression of each gene was 
calculated using the ∆∆Ct method with the ribosomal protein 36B4 used as the internal 
control, as described previously (11, 14, 15). 
 
Chromatin Immunoprecipitation  
MCF-7 cells were stripped of estrogens for 3 days in 5% CD-FBS. Cells were 
pretreated with 1 M BHPI or DMSO (0.1%) as a control for 105 minutes, and then were 
treated with either 10 nM E2 or an ethanol-vehicle control (0.1%) for 45 minutes. ChIP 
was carried out essentially, as previously described (17).   
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siRNA Transfections 
siRNA knockdowns were performed using DharmaFECT1 Transfection Reagent 
and 100 nM ON-TARGETplus non-targeting pool or SMARTpools for ER (ESR1), 
PLC (PLCG1), PERK (EIF2AK3), or pan-IP3R (Dharmacon). The pan-IP3R SmartPool 
consisted of three individual SmartPools, each at 33 nM, directed against each isoform 
of the IP3R (ITPR1, ITPR2, and ITPR3). To knockdown ER, MCF10AER IN9 were 
treated for 16 hours with either human ER SMARTpool (ESR1) siRNA or Non-
targeting Control Pool siRNA. Cells were treated with transfection complex for 16 hours, 
and medium was replaced with DMEM/F12, supplemented with 2% CD-FBS. ER 
knockdown at the mRNA and protein level was assessed every 24 hours following 
transfection. The effects of BHPI on protein synthesis following ER  knockdown were 
assessed 3-days post-knockdown by treating cells with either 0.1% DMSO loading 
control or 100 nM BHPI for the indicated times and protein synthesis was then assessed 
by measuring 35S-Methionine incorporation. Knockdowns of PERK, IP3R, and PLC 
were performed by maintaining MCF-7 cells in MEM containing 5% CD-FBS for 4 days 
prior to plating cells in serum-free MEM.  Cells were treated with transfection complexes 
for 16 hours and medium was replaced with MEM, supplemented with 10% CD-calf 
serum. The effects of BHPI on protein synthesis or calcium signaling were assessed 3-
days post-knockdown. 
 
Immunoblotting  
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Western blotting was carried out as previously described (14, 15, 18). The 
following antibodies were used: ER [6F11] antibody (Biocare Medical, CA), Phospho-
eIF2 (Ser51) (#3398; Cell Signaling Technology), eIF2 (#5324; Cell Signaling 
Technologies, MA), Phospho-eEF2 (#2331; Cell Signaling Technology, MA), eEF2 
(#2332; Cell Signaling Technology, MA), Phospho-p44/42 MAPK (#4370; Cell Signaling 
Technology, MA), p44/42 MAPK (#4695; Cell Signaling Technology, MA), Phospho-
PERK (#3179; Cell Signaling Technology, MA), PERK (#5683; Cell Signaling 
Technology, MA), ATF6 (Imgenex, CA), Phospho-AMPK (#2535; Cell Signaling 
Technology, MA), AMPK (#2603; Cell Signaling Technology, MA), Phospho-AMPKβ1 
(#4181; Cell Signaling Technology, MA), AMPKβ1/2 (#4150, Cell Signaling Technology, 
MA), Phospho-Acetyl-CoA Carboxylase (#3661; Cell Signaling Technology, MA), 
Acetyl-CoA Carboxylate (#3676; Cell Signaling Technology, MA), Phospho-IP3R 
(#8548; Cell Signaling Technology, MA), IP3R (#8568; Cell Signaling Technology, MA), 
Pan-IP3R (sc-28613; Santa Cruz, CA), Phospho-PLC (#2821; Cell Signaling 
Technology, MA), PLC (#5690; Cell Signaling Technology, MA), BiP (#3177; Cell 
Signaling Technology, MA), p58IPK (#2940; Cell Signaling Technology, MA), laminin A/C 
(Santa Cruz, CA), β-Actin (Sigma, MO), and -Tubulin (Sigma, MO). Bound antibodies 
were detected using horseradish peroxidase-conjugated secondary antibodies and 
chemiluminescent immunodetection with an ECL Detection Kit (GE Healthcare, NJ), 
and were visualized using a PhosphorImager. 
 
Nuclear-cytoplasmic Distribution of ER  
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MCF-7 cells were pre-treated with 1 M BHPI or DMSO (0.1%) for 30 minutes, 
followed by 2 hours with or without E2. Nuclear and cytoplasmic extraction was carried 
out on ~6 million cells/treatment using a NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (ThermoScientific). Lamin A/C and -Tubulin, were used as nuclear and 
cytoplasmic markers, respectively. 
 
Protein Synthesis  
Protein synthesis rates were evaluated by measuring incorporation of 35S-
Methionine into newly synthesized protein. Cells were plated at a density of 10,000 
cells/well in 96-well plates. Cells were incubated for 30 minutes with 3 Ci of 35S 
methionine (PerkinElmer, MA) per well at 37o C. Cells were washed two times with PBS, 
and lysed using 30 L of RIPA buffer. Cell lysates were collected in microfuge tubes 
and clarified by centrifugation at 13,000 x g for 10 min at 4o C. Samples were 
normalized to total protein, and the appropriate volume of sample was spotted onto 
Whatman 540 filter paper discs and immersed in cold 10% TCA. The filters were 
washed once in 10% TCA and 3 times in 5% TCA and air dried. Trapped protein was 
then solubilized and the filters were counted. 
 
Calcium Imaging  
Cytoplasmic Ca2+ concentrations were measured using the calcium-sensitive 
dye, Fluo-4 AM. The cells were grown on 35 mm-fluorodish cell culture plates (#FD35-
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100, World Precision Instruments) for two days prior to imaging experiments. The cells 
were loaded with 5 M Fluo-4 AM (Life Technologies, CA) in HEPES-based buffer (140 
mM NaCl, 4.7 mM KCl, 1.13 mM MgCl2, 10 mM HEPES, 10 mM Glucose, pH = 7.4) for 
30 minutes at 37o C before measurement of intracellular calcium. The cells were 
washed three times with HEPES buffer to remove extracellular Fluo4-AM dye and 
incubated with either 2 mM CaCl2 or 0 mM CaCl2 for 10 minutes to complete de-
esterification of the dye.  Confocal images were obtained for one minute to determine 
basal fluorescence intensity, and then the appropriate treatment was added. Confocal 
images were captured using a Zeiss LSM 700 confocal system, Plan-Four 20X objective 
(N.A. = 0.8) and scanned at a resolution of 512x512 pixels (780ms/min). To minimize 
photo-bleaching and photo-toxicity of samples, the laser power was reduced to 7%. For 
fluorescence measurements, the cells were excited at 488 nm, and the emission was 
collected at 525 nm. Images were acquired and analyzed with AxioVision and Zen 
software (Zeiss). Calcium traces were generated by normalizing fluorescence to basal 
fluorescence intensity. Data presented as mean ± standard error (n = 10 individual 
cells). 
 
Protease Sensitivity Assays 
ER LBD (N304-S554) containing an N-terminal 6-His tag, was expressed and 
purified as described previously (19), and stored in Tris-HCl buffer (50 mM Tris-HCl pH 
8.0, 10% glycerol, 2 mM DTT, 1 mM EDTA, and 1 mM Na3VO4). Purified ER LBD 
protein (10 µg) was incubated with 500 nM E2 for 20 min at 37o C. Samples were then 
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treated with either DMSO vehicle, BHPI (1 µM) or inactive Compound 8 (1 µM) and 
incubated for 20 min at 37o C. For partial protease cleavage, the binding mixture was 
added with/without protease K at a concentration of 7.5 ng protease K per µg protein. 
After incubation for 10 min at 22o C, the digestions were terminated by addition of SDS 
sample buffer buffer. The denatured samples were analyzed on a 15% SDS-PAGE gel 
and visualized by coomassie blue staining. 
 
Intrinsic Fluorescence Spectroscopy 
The stock solution of full-length ER was diluted to 400 nM in a Tris-Buffer (50 
mM Tris/HCl pH8.0, 150 mM KCl, 2 mM DTT, 1 mM EDTA, and 10% glycerol). The 
intrinsic fluorescence measurements were carried out using Varian Cary Eclipse 
Fluorescence Spectrophotometer in a 10 mm quartz cuvette. The excitation and 
emission slits were set at 5 nm. Tryptophan fluorescence was measured using an 
excitation wavelength of 295 nm. Emission spectra were collected from 310-380 nm.  All 
spectra were conducted at 37o C. E2 (500 nM), BHPI (500 nM), or inactive compound 88 
(500 nM) was added and incubated at 37oC for 10 min, and then the ERα emission 
spectra were recorded. All the spectra were corrected for baseline in the absence of E2. 
 
Colony Formation Assays  
Assays to assess anchorage-independent cell proliferation in soft agar were 
carried out as previously described (3). Each treatment condition was evaluated on five 
independent sets of cells. Culture medium was changed every 3 days. Colonies were 
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visible after 2 weeks, and total colonies were counted at Day 21 using a dissecting 
microscope. Photographs of colonies were taken using a Zeiss AxioImager2 imaging 
system at 5X magnification. 
 
Mouse xenograft 
All experiments were approved by the Institutional Animal Care Committee 
(IACUC) of the University of Illinois at Urbana-Champaign. The MCF-7 cell mouse 
xenograft model has been described previously (20, 21). At least 12 animals, with 2-4 
tumors per animal, were required per experimental group to maintain significant 
statistical power to detect >25% difference in tumor growth rates. Briefly, estrogen 
pellets (1 mg:19 mg estrogen:cholesterol) were implanted into 60 athymic female OVX 
mice, which were 7 weeks of age. Three days after E2 pellet implantation 1 million MCF-
7, human breast cancer cells per site in matrigel were subcutaneously injected at 2 sites 
in each flank for a total of 4 potential tumors per mouse. When the average tumor size 
reached 17.6 mm2 (4.7 by 4.7 mm), E2 pellets were removed and a lower dose of E2 in 
sealed silastic tubing (1:31 estrogen:cholesterol, 3 mg total weight) was implanted in the 
same site. When the average tumor size reached 23.5 mm2 (5.5 by 5.5 mm), mice were 
divided into 4 groups with tumor size normalized: E2 group, no treatment control (NC) 
group, B_10 group and B_1/B_15 group. E2 silastic tubes in the NC group were 
removed, while E2 silastic tubes in the E2, B_10, and B_1/B_15 groups were retained. 
The E2 and NC group received intraperitoneal injection every other day with 10 ml/kg 
vehicle (2% DMSO, 10% Tween-20, and 88% PBS). The B_10 group received 10 
mg/kg BHPI by intraperitoneal injection every other day. The B_1/B_15 group received 
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1 mg/kg BHPI by intraperitoneal injection every other day for 14 days. Since this 
extremely low BHPI dose had no effect, (average tumor cross-sectional area ~45 mm2) 
they then received 15 mg/kg BHPI every day for another 10 days. Food intake and body 
weight were measured every 4 days and food intake is presented as grams/day. 
Tumors were measured every 4 days with a caliper. Tumor cross sectional area was 
calculated as (a/2)*(b/2)*3.14, where a and b were the measured diameters of each 
tumor. On termination of the experiments mice were euthanized and the tumors were 
excised and weighed. 2 of 60 mice were removed during the course of the study, one 
that failed to form tumors and the other due to unrelated illness. No tumors were 
excluded from analysis, and blinding was not performed.  
 
IP3 Quantitation 
MCF-7 cells were incubated for 10 minutes in 100 nM E2, 10 M BHPI or vehicle. 
Intracellular IP3 levels were determined by extracting the cells, and determining IP3 
levels in an assay based on competition with radiolabeled IP3 for binding to a 
recombinant fragment of IP3R containing the IP3 binding site. Unlabeled IP3 provided a 
standard for the competition assays. 1.5x106 MCF-7 cells were incubated with ice-cold 1 
M trichloroacetic acid (TCA) containing 1 mM EDTA on ice for 15 min. After 
centrifugation, the supernatant was collected and incubated for 15 min. at room 
temperature. The TCA solution was removed by adding two volumes of 1,1,2-Trichloro-
1,2,2-trifluoroethane (TCTFE)-triocylamine solution. The TCTFE-solution was prepared 
by mixing 3:1 (v/v) of TCTFE and trioctylamine (Sigma). Unlabeled IP3, labeled, IP3 and 
the unlabeled IP3R fragment were from Perkin Elmer (Waltham, MA) and were used 
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largely according to the supplier’s directions. Briefly, unlabeled IP3 standards or cell 
extracts were incubated with the working receptor/tracer solution at 1:4 (v/v) for 1 hr. at 
4o C. The samples were sediment by centrifugation at 2,000xg for 20 min and the 
supernatant was discarded. The pellet was suspended in 0.15 M NaOH. After 15 min. at 
room temperature, the samples were mixed with 5 ml of Pico-Fluor Plus scintillation fluid 
(Perkin Elmer, Watham, MA) and radioactivity determined by scintillation counting. IP3 
levels in biological samples were calculated from the standard curve generated using a 
range of unlabeled IP3 concentrations. 
 
EDC Dendrimer  
The EDC dendrimer was prepared and used as previously described (22). 
 
Statistical Analysis 
Calcium measurements reported as mean ± S.E. All other pooled measurements 
are represented as mean ± S.E.M. Two-tailed student t-tests or one way ANOVA with 
post-hoc Fisher’s LSD tests were used to evaluate significance, considering p < 0.05 as 
statistically significant. 
 
Results 
BHPI is Effective in Drug-resistant ER+ Breast and Ovarian Cancer Cells  
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BHPI, (Fig. 1A), strongly inhibited E2-ER induction of an estrogen response 
element (ERE)-luciferase reporter and had no effect on androgen induction of an 
androgen response element (ARE)-luciferase reporter (Fig. 1B).  We tested 9 
compounds closely related to BHPI. One compound was as potent as BHPI, some had 
lower potency and several had negligible ability to inhibit E2-ER induced cell 
proliferation (Fig. 1C). With nanomolar potency, BHPI remained the focus of our studies. 
E2-ER stimulates cell proliferation and metastatic potential in most breast cancers, and 
likely in ovarian, endometrial and cervical cancers (1). We therefore investigated BHPI’s 
effect on proliferation in therapy-sensitive and therapy resistant ER+ breast, ovarian 
and endometrial cancer cells. BHPI completely inhibited proliferation of ER+ breast 
(Fig. 2 A, E, F and G), endometrial (Fig. 2C) and ovarian (Fig. 2B, H, and I) cancer cells, 
and had no effect in counterpart ER- cell lines (Fig. 2D). At 100-1,000 nM, BHPI 
completely blocked proliferation in diverse drug-resistant cell lines:  4-hydroxytamoxifen 
(4-OHT)-resistant ZR-75-1 breast cancer cells (Fig. 2E); tamoxifen and fulvestrant/ICI 
182,780 (ICI)-resistant BT-474 cells (Fig. 2F) (23); epidermal growth factor (EGF) 
stimulated T47D breast cancer cells, which are resistant to 4-OHT, ICI and raloxifene 
(RAL) (Fig. 2G);  Caov-3 ovarian cancer cells, which are resistant to 4-OHT, ICI and 
cisplatin (Fig. 2H) (24), and multidrug resistant OVCAR-3 ovarian cancer cells, which 
are resistant to 5 M ICI (Fig. 2I) and to paclitaxel, cisplatin and other anticancer drugs 
(25, 26). BHPI blocked proliferation in all 15 ER+ cell lines and at 10 M had no effect 
on proliferation in all 12 ER- cell lines tested (Fig. 3). Furthermore, BHPI blocked 
anchorage-independent growth of MCF-7 cells in soft agar (Fig. 4). 
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BHPI Induces Tumor Regression 
We next evaluated BHPI in a mouse xenograft model using MCF-7 cell tumors 
(21). For each tumor, cross-sectional area at Day 0 (~45 mm2) is set to 0%. Control 
(vehicle injected) and BHPI treated mice were continuously exposed to estrogen. After 
daily IP injections for 10 days, the tumors in the vehicle treated mice exhibited 
continued robust growth (Fig. 5, red bars). While BHPI at 1 mg/kg every other day was 
ineffective (Fig. 6A), initiation of 15 mg/kg daily BHPI treatment resulted in rapid 
regression of 48/52 tumors (Fig. 5, blue bars). BHPI easily exceeded the goal of >60% 
tumor growth inhibition proposed as a benchmark more likely to lead to clinical 
response (27). Furthermore, BHPI, at 10 mg/kg every other day, ultimately stopped 
tumor growth and final tumor weight was reduced ~60% compared to controls (Fig. S6A 
and B). BHPI was well tolerated; BHPI-treated and control mice exhibited similar food 
intake and weight gain (Fig. S6C and D). 
 
BHPI is an ER-dependent Inhibitor of Protein Synthesis 
Surprisingly, BHPI greatly reduced protein synthesis in ER+ cancer cells (Fig. 
7A and Fig. 8). If BHPI inhibits protein synthesis through ER, it should only work in 
ER+ cells, and ER overexpression should increase its effectiveness. BHPI inhibited 
protein synthesis in all 15 ER+ cell lines, with no effect on protein synthesis in all 12 
ER- cell lines (Fig. 7A and Fig. 8). BHPI does not inhibit protein synthesis in ER 
negative MCF-10A breast cells, but gains the ability to inhibit protein synthesis when 
ER is stably expressed in isogenic MCF10AER In9 cells (Fig. 7B) (28). Notably, BHPI 
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loses the ability to inhibit protein synthesis when ER in the stably transfected cells is 
knocked down with siRNA (Fig. 7C), or is degraded by ICI (Fig. 7D). Furthermore, 
increasing the ER level in MCF7ERHA cells (29, 30), stably transfected to express 
doxycycline-inducible ER, progressively increased BHPI inhibition of protein synthesis 
(Fig. 7E). BHPI does not work by activating the estrogen binding protein GPR30. BHPI 
has no effect on cell proliferation (Fig. 3) or protein synthesis (Fig. 8) in HepG2 cells that 
contain functional GPR30 (31) and activating GPR30 with G1, did not inhibit protein 
synthesis (Fig. 9A and B). Thus, ER is necessary and sufficient for BHPI to inhibit 
protein synthesis.  
 
BHPI Inhibits Protein Synthesis by a PLC-mediated Opening of the Inositol 
Triphosphate Receptor (IP3R) Ca2+ Channel, Activating the PERK Arm of the UPR  
Inhibiting mTOR signaling did not strongly inhibit protein synthesis (Fig. 9C), 
suggesting BHPI is unlikely to work through mTOR. We next investigated whether BHPI 
inhibits protein synthesis by activating the PERK arm of the UPR. There are three UPR 
arms. The transmembrane kinase PERK is activated by autophosphorylation. P-PERK 
phosphorylates eukaryotic initiation factor 2 (eIF2), inhibiting translation of most 
mRNAs (Fig. 10A) (32, 33). The other arms of the UPR initiate with ATF6 activation 
(Fig. S10B), leading to increased protein folding capacity and activation of IRE1, which 
alternatively splices XBP1, producing active spliced (sp)-XBP1 (Fig. S10C) (32, 33). In 
ER+ MCF-7 and T47D cells, but not in ER- MDA-MB-231 cells, BHPI rapidly inhibited 
protein synthesis (Fig. 11A) and in parallel increased eIF2 phosphorylation (Fig. 11B 
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and C, Fig. 12A). Downstream readouts of eIF2 phosphorylation, CHOP and GADD34 
mRNAs, were rapidly induced by BHPI (Fig 11D and E). Consistent with BHPI inducing 
phosphorylation of eIF2 through activation and autophosphorylation of PERK, p-PERK 
was increased 30 minutes after BHPI treatment (Fig. 11F and Fig. 12A). RNAi 
knockdown of PERK (Fig. 12B) abolished BHPI inhibition of protein synthesis at 30 
minutes and strongly inhibited BHPI-stimulated eIF2 phosphorylation (Fig. 12C and D). 
Since PERK knockdown blocks eIF2 phosphorylation, BHPI is not inhibiting translation 
by activating other upstream kinases that phosphorylate eIF2. Furthermore, BHPI 
rapidly activates the ATF6 and IRE1 arms of the UPR, as shown by increased 
cleaved p50-ATF6 and sp-XBP1 (Fig. 12E and 12F).   
To explore how BHPI activates the UPR, we examined inhibition of protein 
synthesis by known UPR activators. Thapsigargin and Ionomycin, which simulate cell 
stress and activate the UPR by release of Ca2+ from the lumen of the EnR into the 
cytosol (32, 33), but not UPR activators that work by other mechanisms, elicited the 
rapid and near quantitative inhibition of protein synthesis seen with BHPI (Fig. 13A). 
To test whether BHPI alters intracellular Ca2+, we monitored intracellular Ca2+ 
with the calcium sensitive dye Fluo-4 AM. In MCF-7 cells, BHPI produced a large and 
sustained increase in intracellular Ca2+ in the presence of extracellular Ca2+, and a large 
transient increase in intracellular Ca2+ in the absence of extracellular calcium (Fig. 13B). 
Time-dependent changes in cytosol calcium in BHPI-treated MCF-7 cells were 
quantitated (Fig 13B). Since BHPI elicits a large increase in cytosol Ca2+ when there is 
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no extracellular Ca2+, BHPI is acting by depleting the Ca2+ store in the EnR. BHPI had 
no effect on intracellular Ca2+ in ER- HeLa cells (Fig. 13C).  
We next identified the EnR Ca2+ channel that opens after BHPI treatment. The 
inositol triphosphate receptor (IP3R) and ryanodine (RyR) receptors are the major EnR 
Ca2+ channels. Treatment with 2-APB, which locks the IP3R Ca2+ channels closed, but 
not closing the RyR Ca2+ channels with high concentration ryanodine (Ry), abolished 
the rapid BHPI-ER-mediated increase in cytosol Ca2+ and inhibition of protein 
synthesis (Fig. 14A and B). Furthermore, RNAi knockdown of IP3R (Fig. 14C) abolished 
the BHPI-mediated increase in cytosol Ca2+ and inhibition of protein synthesis (Fig. 14D 
and E). IP3R Ca2+ channels are also modulated through protein kinase A (PKA), but 
BHPI did not induce PKA-dependent IP3R-Ser1756 phosphorylation (34) (Fig 14F). 
 
BHPI Strongly Activates Phospholipase C  (PLC), Producing Inositol 1,4,5-
triphosphate (IP3)  
IP3 is produced when the activated phosphorylated plasma membrane enzyme, 
PLC, hydrolyzes PIP2 to diacylglycerol (DAG) and IP3. Supporting a role for PLC, 
siRNA knockdown of PLC (Fig, 14G), abolished the BHPI-mediated increase in cytosol 
Ca2+ (Fig. 14H) and BHPI inhibition of protein synthesis (Fig. 14E), and the PLC 
inhibitor U73122 abolished the BHPI-ER increase in cytosol Ca2+ (Fig. 14H). 
Confirming PLC’s role, BHPI induces rapid PLC-Tyr783 phosphorylation (Fig. 14I), and 
strongly increased IP3 levels (Fig. 14J and K). Supporting the idea that BHPI acts by 
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distorting the newly described weak E2-ER activation of the UPR (15), BHPI induced a 
much larger increase in IP3 levels than E2 (Fig. 14K). 
Rapid BHPI activation of plasma membrane PLC indicates UPR activation is an 
extranuclear action of BHPI-ER. Interestingly, PLC and ER coimmunoprecipitate 
(35). Furthermore, compared to cells expressing basal ER, overexpression of ER in 
MCF7ERHA cells further increased IP3 levels in response to BHPI (Fig. 14J). 
Consistent with extranuclear ER-dependent activation of the UPR, an estrogen-
dendrimer conjugate (EDC) that cannot enter the nucleus (22), induced sp-XBP1, but 
not nuclear estrogen-regulated genes (Fig 15).  
 
BHPI Inhibits E2-ER-regulated Gene Expression and Likely Interacts with ER 
Since BHPI hyperactivates the UPR by distorting a normal action of E2-ER, it 
should interact with ER. Consistent with BHPI binding to E2-ER, BHPI, but not an 
inactive close relative, Compound 8 (Fig. 1C), significantly altered the fluorescence 
emission spectrum of purified ER (Fig. 16A). We also tested whether BHPI alters the 
sensitivity of purified ER ligand-binding domain (LBD) to protease digestion. Addition 
of BHPI followed by cleavage with proteinase K revealed a 15 kDa band in BHPI treated 
ER LBD that was nearly absent in the LBD treated with DMSO or Compound 8 (Fig. 
16B). 
Since BHPI interacts with ER and distorts an extranuclear action of E2-ER, we 
tested whether, independent of its ability to inhibit protein synthesis and activate the 
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UPR, BHPI would also modulate nuclear E2-ER-regulated gene expression. At early 
times when BHPI inhibited E2-ER induction of pS2 mRNA, neither inhibiting protein 
synthesis with CHX, nor activating the UPR with Tunicamycin (TUN) (Fig. 17A) inhibited 
induction of pS2 mRNA (Fig. 16C). BHPI inhibited E2-ER induction of pS2, GREB1, 
XBP1, CXCL2, and ERE-luciferase in ER+ MCF-7 and T47D cells (Fig. S17 B-F), and 
blocked E2-ER down-regulation of IL1-R1 and EFNA mRNA (Fig. 17E and G).  BHPI is 
not a competitive ER inhibitor. Increasing the concentration of E2 by 1,000 fold 
abolished the ability of the competitor antiestrogen ICI to inhibit gene expression, with 
no effect on BHPI inhibition of E2 induction of pS2 mRNA (Fig. 16D). Moreover, BHPI 
did not compete with E2 for binding to ER (Fig. 18A). Since BHPI inhibits E2-ER 
induction and repression of gene expression, BHPI acts at the level of ER and not by a 
general inhibition or activation of transcription. 
 BHPI did not alter ER protein levels or nuclear localization (Fig. 18B and C). 
Chromatin immunoprecipitation (ChIP) showed that BHPI strongly inhibited E2-
stimulated recruitment of ER and RNA polymerase II to the pS2 and GREB1 promoter 
regions (Fig. 16E and Fig. 18D). Consistent with BHPI inducing an ER conformation 
exhibiting reduced affinity for gene regulatory regions, ten-fold overexpression of ER in 
MCF7ERHA cells abolished BHPI inhibition of induction of GREB1 mRNA (Fig. 16F). 
BHPI still kills these cells because ER overexpression enhances BHPI inhibition of 
protein synthesis (Fig. 7E). Taken together, our data provides compelling evidence 
BHPI is a new type of biomodulator, altering both nuclear and extranuclear actions of 
ER. 
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BHPI Rapidly Depletes Intracellular ATP Stores and Activates AMPK 
BHPI treatment results in rapid depletion of EnR Ca2+. To restore EnR Ca2+, the 
cell activates SERCA (Sarco/Endoplasmic Reticulum Ca2+-ATPase) pumps, which 
catalyze ATP-dependent transfer of Ca2+ from the cytosol into the lumen of the EnR. 
Since BHPI opens the IP3R Ca2+ channel, Ca2+ pumped back into the EnR lumen by 
SERCA flows back into the cytosol. This futile cycle rapidly depletes intracellular ATP, 
resulting in activation of AMP-activated protein kinase (AMPK) by AMPK-Thr172 
phosphorylation (Fig. 19A and B). Moreover, the AMPK target, acetyl CoA-carboxylase 
(ACC) is rapidly phosphorylated (Fig. 19B). Since Thapsigargin, which depletes EnR 
Ca2+ by inhibiting SERCA pumps, had no effect on ATP levels (Fig. 19A) and did not 
increase levels of p-AMPK and p-ACC (Fig. 20A), ATP depletion, rather than 
increased cytosol Ca2+ is responsible for AMPK activation. Importantly, pre-blocking 
SERCA-pumps with Thapsigargin, abolished the BHPI-induced decline in ATP levels 
and phosphorylation of AMPK (Fig. 19A). 
 
BHPI Blocks UPR Inactivation by Targeting a Second Site of Protein Synthesis 
Inhibition 
In ER+, but not ER- cells, after ~2 hours, BHPI phosphorylates and inactivates 
eukaryotic elongation factor 2, (eEF2) (Fig. 19C, Fig. 20B and C). eEF2 phosphorylation 
is regulated by a single Ca2+/calmodulin-dependent kinase, eukaryotic elongation factor 
2 kinase (CAMKIII/eEF2K). eEF2K is inhibited by mTORC1-p70S6K and ERK-p90RSK 
127 
 
through eEF2K-Ser366 phosphorylation and activated by Ca2+/calmodulin and AMPK 
(36, 37). BHPI increases cytosol Ca2+ and activates AMPK, but inhibiting AMPK did not 
inhibit eEF2 phosphorylation (Fig. 20D). BHPI also rapidly induces a transient increase 
in ERK1/2 activation (Fig. 20E and F), which stimulates ERK-p90RSK and mTORC1-
p70S6K activation (32). Together, these pathways induce eEF2K-Ser366 phosphorylation 
(Fig. 19D), and prevent increases in p-eEF2 for ~1 hour after BHPI treatment (Fig. 19C 
and Fig. 20G). Consistent with this, blocking ERK activation with U0126 prevented BHPI 
from producing transient declines in eEF2 phosphorylation through inactivation of 
eEF2K (Fig. 20G). 
UPR activation normally induces chaperones, which are critical for resolving EnR 
stress and inactivating the UPR. Thus, conventional UPR activators induce BiP and 
p58IPK chaperones (Fig. 21A and B), promoting transient eIF2 phosphorylation and 
inhibition of protein synthesis (Fig. 20A; Fig. 21C and D). In contrast, BHPI blocks 
induction and reduces levels of BiP and p58IPK protein (Fig. 19E), leading to sustained 
UPR activation and long-term inhibition of protein synthesis (Fig. 3 and Fig. 11B). While 
BHPI blocked increases in p58 protein (Fig. 19E), it robustly induced p58 mRNA (Fig. 
19F), suggesting that inhibiting protein synthesis at the second site prevented 
translation of chaperone mRNAs required to resolve UPR activation.  
 
Discussion 
BHPI and estrogen share the same ER-dependent pathway for UPR activation: 
Activation of PLC producing IP3, opening of the IP3R Ca2+ channels, release of EnR 
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Ca2+, and activation of the PERK, IRE1 and ATF6 arms of the UPR (Fig. 22). We 
recently reported that as an early component of the proliferation program, E2-ER 
weakly and transiently activates the UPR. We showed that E2-ER elicits a mild and 
transient activation of the PERK arm of the UPR, while simultaneously increasing 
chaperone levels and protein folding capacity by activating the IRE1 and ATF6 arms 
of the UPR (15). BHPI distorts this normal action of E2-ER by increasing the amplitude 
and duration of UPR activation. Compared to E2, BHPI hyperactivates PLC, producing 
much higher IP3 levels, Ca2+-release from the EnR, and UPR activation. BHPI inhibits 
protein synthesis by strongly activating the PERK arm of the UPR. Knockdown of ER, 
PLC, IP3R and PERK blocked BHPI inhibition of protein synthesis. While BHPI 
activates the IRE1 and ATF6 UPR arms, BHPI prevents the synthesis of chaperones 
required to inactivate the UPR by acting at later times to inhibit protein synthesis at a 
second site. Because the cell attempts to restore EnR Ca2+ while the IP3R Ca2+ 
channels remain open, BHPI rapidly depletes ATP (Fig. 22), resulting in activation of 
AMPK. Working together, long-term inhibition of protein synthesis, ATP depletion and 
AMPK activation enable BHPI to block cell proliferation, and often kill, ER+ cancer 
cells. Supporting BHPI targeting PLC and the UPR through ER, independent of its 
effects on the UPR, BHPI inhibits E2-ER-mediated induction and repression of gene 
expression.  
BHPI and E2 activation of plasma membrane-bound PLC, resulting in increased 
IP3, is an extranuclear action of ER. Increasing the level of ER, increased IP3 levels. 
Consistent with ER and PLC interaction, they coimmunoprecipitate (35). BHPI and E2 
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induce Ca2+ release in 1 min., too rapidly for action by regulating nuclear gene 
expression (15). Furthermore, a membrane-impermeable estrogen-dendrimer induces 
the UPR marker sp-XBP1, but not nuclear E2-ER-regulated genes. 
 The UPR plays important roles in tumorigenesis, therapy resistance, and cancer 
progression (15, 38). Moderate and transient UPR activation by E2 and other activators 
promotes an adaptive stress response, which increases UPR expression and confers 
protection from subsequent exposure to higher levels of cell stress (15, 39, 40). In 
contrast, sustained UPR activation triggers cell death. Since most current anticancer 
drugs inhibit a pathway or protein important for tumor growth or metastases, most UPR 
targeting efforts use the same strategy and focus on inactivating a protective stress 
response by inhibiting UPR components (41). UPR overexpression in cancer is 
associated with a poor prognosis (15), suggesting that sustained lethal hyperactivation 
of the UPR by BHPI represents a novel alternative anticancer strategy.  
 BHPI can selectively target cancer cells, because its targets, ER and the UPR, 
are both overexpressed in breast and ovarian cancers (15, 30, 38, 42). Cells expressing 
low levels of ER, more typical of non-transformed ER containing cells, such as PC-3 
prostate cancer cells, were less sensitive to BHPI inhibition of protein synthesis (Fig. 3), 
while doxycycline-treated MCF7ERHA cells expressing very high levels of ER 
exhibited near complete inhibition of protein synthesis (Fig. 7E). Consistent with low 
toxicity, in the xenograft study, BHPI-treated mice showed no evidence of gross toxicity.  
Despite a role for ER in gynecological cancers, most ovarian cancer cells show 
little dependence on estrogens for growth and endocrine therapy is largely ineffective. 
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Other non-competitive ER inhibitors have not demonstrated effectiveness in these 
cells. BHPI is highly effective in several breast and ovarian cancer drug-resistance 
models and extends the reach of ER biomodulators to gynecologic cancers that do not 
respond to current endocrine therapies. BHPI’s effectiveness in a broad range of ER-
containing breast, ovarian and endometrial cancer cells is consistent with recent 
findings demonstrating that female reproductive cancers exhibit common genetic 
alterations and might respond to the same drugs (43), and with our finding that E2-ER 
weakly activates the UPR in breast and ovarian cancer cells (15). 
With its sub-micromolar potency, effectiveness in a broad range of therapy 
resistant cancer cells, ability to induce substantial tumor regression and unique mode of 
action, BHPI is a promising small molecule for therapeutic evaluation and mechanistic 
studies.  
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Figure 4.1. BHPI and structurally related compounds selectively inhibit estrogen-
dependent cell proliferation and E2-ER mediated gene expression. (A) Structure 
of BHPI (3,3-bis(4-hydroxyphenyl)-7-methyl-1,3,dihydro-2H-indol-2-one). (B) Dose 
response studies of the effect of BHPI on 17-estradiol (E2) induction of ERE-luciferase 
activity in ER positive T47D-kBluc breast cancer cells (black bars) and for 
dihydrotestosterone-androgen receptor (DHT-AR) induction of prostate specific antigen 
(PSA)-luciferase in ER negative HeLaA6 cells (open bars). HeLaA6 cells are stably 
transfected to express AR and a PSA-luciferase reporter. Data is the mean ± SEM (n = 
3 sets of cells). (C) Inhibition of cell proliferation in ER+ T47D breast cancer cells by 
BHPI and structurally related compounds.  
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Figure 4.2. BHPI selectively inhibits proliferation of ER+ cancer cells sensitive or 
resistant to drug therapy. BHPI inhibits proliferation of ER+ (A) MCF-7 breast, (B) 
PEO4 ovarian, and (C) ECC-1 endometrial cancer cells with no effects on (D) 
counterpart ER- cancer cells. Effects of BHPI on proliferation of drug-resistant cells: 
Tamoxifen- and ICI-resistant (E) ZR-75-1 cells and (F) BT-474 breast cancer cells. (G) 
T47D cells treated with 1 M BHPI or competitor antiestrogens (4-OHT, RAL, ICI) in the 
presence or absence of E2 and/or EGF. Proliferation of (H) cisplatin resistant Caov-3 
ovarian cancer cells and (I) multi-drug resistant OVCAR-3 ovarian cancer cells treated 
with BHPI, or the antiestrogens 4-OHT or ICI. Concentrations: E2, 1 nM (E, G, H) or 10 
nM (A-C, F, I); EGF, 50 ng/mL (G); ICI, 1 μM (E, G, H), 5 μM (I); 4-OHT, 1 μM (E, G, H); 
RAL, 1 μM (G) “•” denotes cell number at day 0. Hatched bars denote antiestrogens (4-
OHT, RAL, or ICI). Cell proliferation is expressed as mean ± SEM (n = 6). 
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Figure 4.3. BHPI selectively inhibits cell proliferation in ER positive cancer cells. 
Effects of BHPI on cell proliferation in 15 ER positive (colored bars) and 12 ER 
negative (black bars) cell lines. Cell lines are grouped by tissue of origin (breast, ovary, 
cervix, prostate, lung and liver). “•” on each graph denotes the number of cells at the 
start of the experiment. Most cell proliferation studies were for 3 or 4 days in 10 nM E2. 
Since we recently found that our BG-1 cells are genetically identical to MCF-7 cells, that 
data is presented as BG-1/MCF-7. Data is the mean ± SEM (n = 6). 
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Figure 4.4. BHPI inhibits anchorage-independent growth of MCF-7 cells in soft 
agar. 5,000 MCF-7 cells were plated into top agar. Cells were treated with medium 
containing DMSO (vehicle) and either, 10 nM E2 or Ethanol (vehicle), or 1 M BHPI and 
10 nM E2. Medium was changed every 3 days. After 21 days, colonies were counted 
and photographed at 5x magnification. For each treatment, the bar graph represents the 
average of the total number colonies per well with a diameter >0.5 mm. Data is the 
mean ± SEM (n = 6). 
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Figure 4.5. BHPI induces tumor regression in a mouse xenograft. Change in tumor 
cross sectional area in mouse MCF-7 xenografts after 10 days of daily IP injections of 
either 15 mg/kg BHPI (blue) or vehicle control (red). Tumors had an average starting 
cross-sectional area of ~45 mm2. For each tumor, area at day 0 was set to 0% change. 
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Figure 4.6. BHPI inhibits tumor growth in a mouse xenograft model of breast 
cancer and is not toxic. (A) MCF-7 tumor growth in athymic mice was monitored by 
measuring tumor diameter with a caliper every 4 days. The E2 and NC group received 
vehicle injection, while the B_10 group was injected with 10 mg/kg BHPI every other 
day. The B_1/B_15 group received the extremely low dose of 1 mg/kg BHPI every other 
day for 14 days. This very low dose of BHPI had no effect on tumor growth. They then 
received 15 mg/kg BHPI every day until the end of the study (* denotes change in 
dosage). Tumor size was represented as tumor cross sectional area (mm2). Each tumor 
was analyzed individually, and data are expressed as mean ± SEM (n = 52). (B) Mice 
were sacrificed and tumor weights were recorded. Data is expressed as mean ± SEM (n 
= 52) and analyzed using one way ANOVA with post hoc Fisher’s LSD test. Different 
letters indicate significant differences between groups (p <0.05). (C) Mouse body 
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weight, measured every 4 days after initiation of drug injection. Data expressed as 
mean ± SEM (n = 13). (D) Mouse food intake, measured every 4 days after initiation of 
drug injection. Data expressed as mean ± SEM (n = 13). BHPI treatment had no effect 
on body weight or food intake and was therefore not overtly toxic. 
 
 
Figure 4.7. BHPI selectively inhibits protein synthesis in ER positive cancer cells 
by activating PLC, depleting endoplasmic reticulum Ca2+, and activating the 
UPR. (A) Protein synthesis in BHPI-treated ER+ and ER- cells (n = 4). CHX, 
cycloheximide. (B) ER is sufficient to make a cell sensitive to BHPI inhibition of protein 
synthesis. Protein synthesis in parental ER- MCF10A cells and ER expressing 
MCF10AER IN9 cells (n = 4). (C) RNAi knockdown of ER abolishes BHPI inhibition of 
protein synthesis. Protein synthesis in MCF10AER IN9 cells treated with non-coding (NC) 
siRNA or ER siRNA SmartPool followed by 100 nM BHPI (n = 4). (D) Protein synthesis 
and immunoblot analysis of ER protein levels in MCF10AER IN9 cells pre-treated with 1 
M ICI for 24 hours to degrade ER, followed by treatment with 100 nM BHPI (n = 4). 
(E) Residual protein synthesis (untreated cells are set to 100%) after treatment with 1 
M BHPI in Doxycycline-treated MCF7ERHA cells expressing increasing levels of 
ER (n = 6). Western blot shows ER levels in each sample.  
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Figure 4.8. BHPI selectively inhibits protein synthesis in ER positive cells. 
Comparison of ER protein levels and the effects of BHPI treatment on protein 
synthesis in 23 cell lines. The number of samples was too large to run on a single gel 
and the data is from 3 identically processed gels. Protein synthesis was determined by 
incorporation of 35S-methionine into protein. Incorporation with no added BHPI was set 
to 100%. In general, protein synthesis in cells expressing moderate or high levels of 
ER was robustly inhibited by 100 nM BHPI (yellow bars), while 10,000 nM BHPI 
(orange bars), the highest concentration tested, had very little or no effect on protein 
synthesis in ER negative cells. Cells expressing low levels of ER, more typical of 
non-transformed ER containing cells, such as PC-3 prostate cancer cells, were much 
less sensitive to BHPI inhibition of protein synthesis. As a control, cycloheximide (CHX) 
potently inhibited protein synthesis in all the cell lines.  Data is the mean ± SEM (n = 4). 
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Figure 4.9. Activation of the estrogen binding protein, GPR30, or inhibition of 
mTOR, have minimal effects on protein synthesis. Effects of the GPR30 activator, 
G1, on (A) MCF-7 and (B) BG-1/MCF-7 cells. Cells were plated at 10,000 cells/well, the 
indicated concentrations of G1 (0-100 nM) were added for the times indicated, and 35S-
Methionine incorporation was used to assess rates of protein synthesis. Protein 
synthesis with no added G1 was set to 100%. (C) The effects of rapamycin (RAP) on 
protein synthesis in MCF-7 cells in the absence of growth factors (blue bars), or in the 
presence of 10 nM E2 (red bars) or 10 μg/ml Insulin (green bars). Inhibition of mTORC1 
with rapamycin blocks insulin-dependent increases in protein synthesis (green bars) 
and substantially blocks estrogen-dependent increases in protein synthesis (red bars). 
In contrast, BHPI and cycloheximide (CHX) treatment elicit near-quantitative inhibition of 
protein synthesis, far below baseline levels of protein synthesis (blue bars). Data is 
mean ± SEM (n = 4). 
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Figure 4.10. Endoplasmic reticulum (EnR) stress activates the three arms of the 
UPR. (A) EnR stress induces the oligomerization and phospho-activation of the 
transmembrane kinase PERK. P-PERK phosphorylates eukaryotic initiation factor 2 
(eIF2), leading to inhibition of protein synthesis and a reduction in the endoplasmic 
reticulum protein folding load (32, 33). Reduced protein synthesis increases levels of 
the transcription factor, ATF4. ATF4 induces the transcription factor CHOP, which 
induces GADD34 and several pro-apoptotic genes. (B) EnR stress promotes the 
translocation of the transmembrane protein, p90-ATF6α, from the EnR to the Golgi 
Apparatus, where it encounters proteases that liberate the N-terminal fragment of 
ATF6α (p50-ATF6). p50-ATF6 increases the protein-folding capacity of the EnR by 
inducing EnR-resident chaperones, including BiP and GRP94 (32, 33, 44). (C) EnR 
stress induces the oligomerization and phospho-activation of the transmembrane 
protein, IRE1 (32, 33, 45). Activated IRE1 removes an intron from full-length XBP1 
(fl-XBP1) mRNA, producing spliced (sp)-XBP1 mRNA, which is subsequently translated 
into sp-XBP1 protein (sp-XBP1). sp-XBP1 increases the protein-folding capacity of the 
EnR and turnover of misfolded proteins by inducing EnR resident-chaperone protein 
genes (BiP, HEDJ, SERP1), EnR-associated degradation (ERAD) genes and alters 
mRNA decay and translation (32, 33).  
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Figure 4.11. In ER positive cell lines, BHPI rapidly inhibits protein synthesis by 
activating the PERK arm of the UPR. (A) Time course of BHPI inhibition of protein 
synthesis. ER positive MCF-7, T47D, and BG-1/MCF-7 cells were incubated for the 
indicated times in 1 M BHPI. Set to 100% was incorporation of 35S-methionine into 
protein at time = 0. Data is mean ± SEM (n = 4 sets of cells). At 30 min. in BHPI, 35S-
methionine incorporated into protein was reduced by ~50%. (B) In the presence [+E2], 
or absence (-E2) of estrogen, BHPI increases p-eIF2α (Ser-51) in ER+ MCF-7, BG-
1/MCF-7, and T47D cells. In the absence of estrogen, BHPI increases eIF2 
phosphorylation in ER+ MCF-7 cells. (C) BHPI does not increase p-eIF2α in ER 
negative MDA MB-231 cells. Since the UPR activator tunicamycin (TUN) increased p-
eIF2 in these cells, the absence of BHPI induced phosphorylation of eIF2 in the MDA 
MB-231 cells was not due to the inability of UPR activation to induce eIF2 
phosphorylation. (D) Induction of CHOP and GADD34 mRNA in MCF-7 cells following 
treatment with 1 M BHPI, as determined by qRT-PCR. (E) Induction of CHOP mRNA 
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in BG-1/MCF-7 cells following treatment with 1 M BHPI. Increased levels of ATF4 
induce the transcription factor, CHOP, which then induces GADD34. Increased 
phosphorylation of eIF2 results in translational upregulation of the transcription factor, 
ATF4. ATF4 contains short, inhibitory upstream open reading frames (uORFs), which 
normally inhibit translation of ATF4 mRNA (10). Under conditions of reduced eIF2 
availability, the inhibitory uORFs are skipped, allowing ATF4 translation. (F) Time 
course of phosphorylation of PERK (Thr-980) and total PERK protein levels following 
treatment with BHPI in MCF-7 cells. PERK-Thr980 phosphorylation serves as a marker 
of PERK activation.  
 
  
143 
 
 
Figure 4.12. BHPI selectively inhibits protein synthesis in ER positive cancer 
cells by activating all three arms of the UPR. (A) Time course of phosphorylation of 
PERK and eIF2 following BHPI treatment of MCF-7 cells. (B) Western blot analysis of 
PERK protein levels following treatment of MCF-7 cells with either 100 nM non-coding 
(NC) or PERK siRNA SmartPool  (C) Protein synthesis and (D) eIF2 phosphorylation 
after 4-day treatment of MCF-7 cells with either 50 nM non-coding (NC) siRNA or PERK 
siRNA, followed by treatment with BHPI (n = 4). (E) Effects of BHPI on levels of spliced-
XBP1 mRNA (sp-XBP1). -E2 samples set to 1 (n = 3).  (F) Western blot analysis 
showing full-length (p90-ATF6) and cleaved p50-ATF6 in BHPI-treated cells and 
effect of BHPI on levels of spliced-XBP1 mRNA (sp-XBP1). Data is mean ± S.E.M.  
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Figure 4.13. BHPI activates the UPR through depletion of endoplasmic reticulum 
calcium stores in ER+ MCF-7 breast cancer cells, but not in ER- HeLa cervical 
cancer cells. (A) Protein synthesis in MCF-7 cells treated for 2 hours with UPR 
activators (n = 6). Effect of BHPI and Thapsigargin (THG) on intracellular calcium levels 
in (B) ER+ MCF-7 breast cancer cells and (C) ER- HeLa cervical cells. Although BHPI 
has no effect, HeLa cells remain sensitive to Thapsigargin. Cells visualized with the 
Ca2+ sensitive dye Fluo-4 AM. Low levels of basal [Ca2+] are blue and then green, 
whereas higher levels of [Ca2+] are seen as red, with the highest levels white. Trace 
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represents calcium following treatment with Thapsigargin or BHPI. Intensity was 
normalized to the basal signal, which was set to 1. Data is mean ± SEM (n = 10). 
 
Figure 4.14. Effects of BHPI on IP3R, IP3, and PLC. (A) BHPI increases intracellular 
calcium levels. Visualization of intracellular Ca2+ using Fluo-4 AM; BHPI (1 M) was 
added to MCF-7 cells at 30 sec. Color scale from basal Ca2+ to highest Ca2+: blue, 
green, red, white. (B) Inhibiting opening of the endoplasmic reticulum IP3R Ca2+ channel 
abolishes BHPI inhibition of protein synthesis. The ryanodine and IP3R Ca2+ channels 
were pre-blocked with 100 M ryanodine (RyR) and 100 μM 2-amino propyl-benzoate 
(2-APB), respectively, followed by 70 nM BHPI for 3 hours (n = 4). (C) Western blot 
analysis of pan-IP3R protein levels after treatment of MCF-7 cells with either 100 nM 
non-coding (NC) SmartPool siRNA or 100 nM SmartPool IP3R siRNA. (D) Quantitation 
of cytosolic Ca2+ levels after treating MCF-7 cells with either 50 nM non-coding (NC) 
146 
 
siRNA, pan IP3R siRNA SmartPool, followed by treatment with BHPI (n = 10). IP3R 
SmartPool contained equal amounts of three individual SmartPools directed against 
each isoform of IP3R. (E) Effects of BHPI on protein synthesis in MCF-7 cells treated 
with either 100 nM NC siRNA, pan-IP3R siRNA, or PLC siRNA SmartPool (n = 4). (F) 
Time course of phosphorylation of the IP3R Ca2+-channel and total IP3R following 
treatment with BHPI. Phosphorylation of IP3R at Ser-1756 by cyclic AMP-dependent 
protein kinase A (PKA) regulates the activity of the IP3R Ca2+-channel. While BHPI had 
no effect, the MCF-7 cells contain a functional protein kinase A pathway since the 
protein kinase A activators, IBMX and Forskolin, increased phosphorylation of IP3R. (G) 
Western blot shows PLC protein levels following treatment of MCF-7 cells with either 
100 nM non-coding SmartPool siRNA or 100 nM SmartPool PLC  siRNA. (H) Effects of 
BHPI on cytosol Ca2+ following either PLC knockdown or blocking PLC activation with 
U73122. Western blot shows PLC protein levels following treatment of MCF-7 cells 
with either 100 nM non-coding SmartPool siRNA or 100 nM SmartPool PLC  siRNA. (I) 
Effects of BHPI on phosphorylation and activation of PLC. Phosphorylation of PLC at 
Tyr-1756 regulates the activity of PLC. MCF-7 cells were treated for 10 min. with 1 M 
BHPI. (J) Quantitation of intracellular IP3 levels following treatment of MCF-7 cells for 10 
min. with E2 or BHPI (n=3) (K) Effects of overexpressing ER on BHPI-induced 
increases in IP3 levels. ER in MCF7ERHA cells was induced with DOX as described 
in Figure 3E. IP3 levels were determined 10 min. after treatment with 1 M BHPI. Data 
is mean ± SEM (n=3). Data is mean ± S.E.M. Different letters indicate a significant 
difference among groups (p < 0.05) using one-way ANOVA followed by Tukey’s post 
hoc test. 
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Figure 4.15. Effects of estrogen-dendrimer-conjugate (EDC) on UPR activation 
and E2-regulated genes. Comparison of effects of 17-estradiol (E2) and estrogen-
dendrimer-conjugate (EDC) on the ability of ER to activate (A) GREB1, (B) PI-9, and 
(C) Fos expression. These are classical estrogen-regulated genes. (D) Comparison of 
the effects of E2 and EDC on the ability to induce spliced-XBP1 (sp-XBP1), which is a 
widely used marker of UPR activation (see UPR model in Figure S7C). 
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Figure 4.16. BHPI interacts with ER and inhibits E2-ER regulated gene 
expression. (A) Fluorescence emission spectra of full-length ER in the presence of E2 
and either DMSO, 500 nM BHPI, or 500 nM of the BHPI-related inactive Compound 8 
(C8). (B) ER LBD was subjected to proteinase K digestion in the presence of DMSO 
vehicle, C8, or BHPI. Bands were visualized by Coomassie-staining. (C) qRT-PCR 
showing pS2 mRNA in MCF-7 cells pre-treated for 0.5 hours with BHPI, cycloheximide 
(CHX), Tunicamycin (TUN), Thapsigargin (THG), or DMSO, followed by treatment with 
or without E2 for 2 hours. (D) BHPI is a non-competitive ER inhibitor. qRT-PCR 
showing pS2 mRNA in MCF-7 cells treated with BHPI or the competitive inhibitor ICI, 
and low (1 nM) or high (1,000 nM) E2. (E) ChIP showing effect of BHPI on recruitment of 
E2-ER (green bars) and RNA polymerase II (RNAP, yellow hatched bars) to the 
promoter region of pS2. (F) qRT-PCR showing GREB1 mRNA levels in MCF7ERHA 
cells after 1 day + or – doxycycline (DOX), pre-treated for 30 minutes with BHPI or 
DMSO, followed by 4 hours with or without E2. Concentrations: E2, 500 nM (A and B), 
10 nM (C-F); BHPI, 500 nM (A) or 1 μM (B-F); C8, 500 nM (A) or 1 μM (B); CHX, 10 μM; 
THG, 1 μM; TUN, 10 μg/ml. Data is mean ± SEM (n = 3). * P < 0.05, ** P < 0.01, ***P < 
0.001, compared with +E2 samples. n.s., not significant. 
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Figure 4.17. BHPI inhibits E2-ER regulated gene expression. (A) Comparison of 
the effects of BHPI, the protein synthesis inhibitor cycloheximide (CHX), and the UPR 
activator Tunicamycin (TUN) on protein synthesis. Since protein synthesis was robustly 
inhibited by CHX after 120 minutes, this time was used in the gene expression studies. 
Effects of BHPI on E2-ER induction of (B) pS2, (C) GREB1 and (D) CXL2 mRNAs and 
(E) XBP1 in MCF-7, T47D and BG-1/MCF-7 cells. (F) Dose response studies of the 
effect of BHPI on E2-ER induction of ERE-luciferase activity in ER positive T47D-
kBluc breast cancer cells (black bars) and for dihydrotestosterone-androgen receptor 
(DHT-AR) induction of prostate specific antigen (PSA)-luciferase in ER negative 
HeLaA6 cells (open bars). HeLaA6 cells are stably transfected to express AR and a 
PSA-luciferase reporter. Supporting specificity of BHPI, it did not inhibit DHT-AR 
induction of ARE-luciferase. BHPI blocks E2-ER down-regulation of EFNA1 in MCF-7 
cells (E) and IL1-R1 in T47D cells (G). Data is mean ± SEM (n = 3).  
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Figure 4.18. BHPI is a non-competitive inhibitor that reduces binding of E2-ER to 
gene regulatory regions. BHPI does not compete with estrogens for binding to 
ER. (A) Competitive radioligand binding assay comparing the ability of E2 and BHPI to 
compete with [3H] estradiol (E2) for binding to ER. The relative binding affinity (RBA) of 
BHPI for the estrogen-binding pocket of ER was determined using 0.2 nM [3H] E2 and 
a range of BHPI concentrations. RBA values were determined from the competitive 
radiometric binding assay (22, 46).  Values are expressed as percentages relative to the 
affinity of the standard, E2 = 100%.  (B) Western blots showing that at early times after 
treatment with 1 M BHPI, ER protein levels are nearly unchanged. (C) Western blot 
showing that treatment of MCF-7 cells with 1 M BHPI does not inhibit nuclear 
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localization of ER. -Tubulin and lamin A/C were controls for the cytoplasmic and 
nuclear fractions, respectively. ER protein levels and nuclear localization were 
assessed 2 hours after treatment, which was the same time used to assess 
endogenous mRNA levels of E2-ER regulated genes via qRT-PCR. (D) ChIP shows 
BHPI inhibits recruitment of E2-ER (black bars) and RNA polymerase II (RNAP, 
hatched bars) to the GREB1 promoter region. Data is mean ± SEM (n = 3). * Significant 
at (p <0.05). 
152 
 
 
Figure 4.19. BHPI depletes intracellular ATP stores, activates AMPK, and inhibits 
protein synthesis at a second site. (A) Inhibiting SERCA pumps with Thapsigargin 
(THG) prevents BHPI from reducing intracellular ATP levels. Western blot showing 
effect of THG (1 μM) or BHPI (1 μM) treatment of MCF-7 cells on AMPKα-Thr172 
phosphorylation. ATP levels in MCF-7 cells treated with 1 μM BHPI, or 1 μM BHPI and 
1 μM THG (n = 5). (B) Western blot analysis of the time course of AMPKα (Thr-172), 
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AMPKβ (Ser-108), acetyl CoA carboxylase (ACC) (Ser-79) phosphorylation in BHPI-
treated MCF-7 cells. AMPKα-Thr172 and AMPKβ-Ser108 phosphorylation are required for 
AMPK activation. (C) Western blot analysis of eEF2 phosphorylation (Thr-56) over time 
in BHPI-treated ERα+ MCF-7 cells. (D) Western blot analysis showing the time course of 
decreasing eEF2K (Ser-366) phosphorylation in BHPI-treated MCF-7 cells. Ser-366 
dephosphorylation activates eEF2K. (E) qRT-PCR analysis showing changes in p58IPK 
mRNA and Western blot analysis showing p58IPK and BiP protein after treatment with 
BHPI (n = 3).  -E2 set to 1. 
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Figure 4.20. Conventional UPR activators do not induce phosphorylation of eEF2, 
but induces transient eIF2 phosphorylation, transient inhibition of protein 
synthesis, and induction of chaperones. (A) Analysis of the time course of 
Thapsigargin (THG) effects on phosphorylation of eIF2 (Ser-51), AMPK (Thr-172), 
ACC (Ser-79), and eEF2 (Thr-56). Unlike BHPI, Thapisgargin does not induce 
phosphorylation of eEF2 but induces transient phosphorylation of eIF2. Western blots 
of the time course of BHPI effects on phosphorylation of eEF2 (Thr-56) in (B) ER 
positive T47D and (C) ER negative HeLa cells. T47D Cells were pre-treated with 10 
nM E2 for 24-hours. eEF2 is essential for protein synthesis, and eEF2-Ser56 
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phosphorylation inactivates eEF2, blocking the elongation step of protein synthesis. The 
positive controls, Forskolin (FOR) and Rottlerin (ROT) induce robust eEF2 
phosphorylation, demonstrating eEF2 retains the capacity for phosphorylation in HeLa 
cells. (D) Inhibiting AMPK phosphorylation and activation with ST-609 did not block 
BHPI-stimulated phosphorylation of eEF2. Effects of BHPI on Thr-202/Thr-204 
phosphorylation of p44/p42 MAPK (p-ERK) in ER positive (E) MCF-7 cells and (F) 
T47D cells. Activation of p44/p42 MAPK promotes the phosphorylation and inactivation 
of eEF2K. The classical ERK activator, EGF (20 ng/ml), served as a positive control for 
ERK1/2 phosphorylation. As a control, cells were treated with 10 μM UO126 for the 
indicated times. U0126 inhibits the upstream kinase MEK1/2, inhibiting ERK1/2 
phosphorylation. UO126 pre-treatment was for 2 hours. (G) Effects of blocking ERK 
activation with U0126 on BHPI-induced phosphorylation of eEF2. By inhibiting the ERK 
pathway, UO126 allows eEF2K to be active and the reduced activation seen at 0.5 and 
1 hours due to BHPI-induced ERK activation is abolished. 
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Figure 4.21. The UPR activator, Tunicamycin, reversibly activates the UPR. 
Induction of BiP and p58IPK normally helps resolve UPR stress and reverses UPR 
activation. Western blot analysis showing the time course of Tunicamycin (TUN) 
induction of BiP (A) and p58IPK (B) in MCF-7 cells. Data in panel A is from ((47), 
supplementary figures) (C) Western blot analysis of phosphorylation of eIF2 following 
TUN treatment. TUN induces transient phosphorylation of eIF2. (D) Time course of 
TUN inhibition of protein synthesis. Consistent with transient phosphorylation of eIF2 
and resolution of UPR stress, protein synthesis begins to recover at 4 hours after 
treatment with TUN. Data is mean ± SEM (n = 3). (A-D) 24-hour pre-treatment with 10 
nM E2. 
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Figure 4.22. Model of BHPI. In ER+ cancer cells, BHPI rapidly hyperactivates plasma 
membrane PLC, generating IP3, which opens EnR IP3R calcium channels, rapidly 
depleting EnR Ca2+ stores. This stimulates activation all 3 arms of the UPR. Activating 
the PERK arm of the UPR leads to phosphorylation of eukaryotic initiation factor 2 
(eIF2) and potent inhibition of protein synthesis. The cell attempts to restore EnR Ca2+ 
levels, but the open EnR IP3R calcium channel leads to an ATP-depleting futile cycle, 
resulting in activation of the energy sensor AMPK and phosphorylation of eukaryotic 
elongation factor 2 (eEF2). Inhibiting protein synthesis at a second site prevents 
synthesis of chaperones and other proteins that resolve UPR stress. Independent of 
BHPI’s effects on protein synthesis, BHPI inhibits E2-ER regulated gene expression. 
Together, these effects promote cell death in ER+ cancer cells.  
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CHAPTER 5 
DISCUSSION 
The importance of estrogens (E2), acting through estrogen receptor  (ER), in 
stimulating the proliferation and metastases of most breast cancers is demonstrated by 
the successful use of aromatase inhibitors, tamoxifen and other endocrine therapies (1-
4). Yet, the development of resistance to tamoxifen and to aromatase inhibitors is a 
prevalent problem in breast cancer treatment (2). Selection and outgrowth of breast 
cancers resistant to endocrine therapy is common (2, 5, 6), and most deaths due to 
breast cancer are in patients with ER+ tumors (5). While 30-70% of epithelial ovarian 
cancers are ER positive (1), most tumors display de novo resistance to endocrine 
therapy (7-9). Therapeutic options for these resistant tumors are poor and nearly two-
thirds of ovarian cancer patients die within 5 years (10). The presence of ER in most 
therapy-resistant breast and gynecologic cancers suggested the presence of additional 
modes of ER action potentially targetable with small molecules. 
To identify new small molecule inhibitors that target the estrogen-ER axis in 
cancer cells resistant to current therapies, we developed and implemented an unbiased 
pathway-directed screen of ~150,000 small molecules. This type of unbiased screen 
asks the cell to tell us what interactions and pathways are susceptible to targeting by 
small molecules, using a readout of inhibition of E2-ER-mediated gene expression. 
Candidate inhibitors were then evaluated in more detail for the ability to inhibit estrogen-
dependent growth of ER+ MCF-7 breast cancer cells, with little or no effect on the 
growth of ER- MDA-MB-231 cells. The ~40 most potent inhibitors were further tested 
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for specificity using non-tumorigenic, ER- MCF-10A human mammary epithelial cells. 
The screening conditions were designed to minimize the possibility that our small 
molecule hits would be ligands that compete with estradiol for binding in the ligand-
binding pocket of ER. Since competitors would be expected to show reduced inhibition 
of ER action at high concentrations of 17-estradiol, we tested ~40 of the most potent 
hits for the ability to inhibit ER-mediated transactivation in the presence of 1 nM 
estradiol and 500 nM E2. None of the inhibitors appeared to function as competitive 
ligands. 23 compounds, comprising 18 distinct structural families, specifically inhibited 
the estrogen dependent growth of MCF-7 cells with IC50s < 1 M.  Inhibitors with 
different modes of action exhibited a broad range of potency, with highly potent 
inhibitors targeting several different sites. 
From the screen, the selective non-competitive ER inhibitor, BHPI, was 
identified and became the candidate lead compound. BHPI blocks cell proliferation and 
kills tamoxifen and fulvestrant-resistant ER+ cancer cells, with no effect on ER- cells. 
In a mouse xenograft, BHPI induced rapid and substantial regression of large pre-
existing tumors. BHPI’s effectiveness in a broad range of ER-containing breast, 
ovarian and endometrial cancer cells is due to its ability to target the unfolded protein 
response (UPR) pathway. The UPR is inactive in most normal cells, but is commonly 
overexpressed in advanced-stage and highly metastatic cancers (11-14). While 
standard UPR activators are nonspecific and highly toxic, BHPI selectively targets ER+ 
cancer cells by activating the UPR through the same pathway used by E2-ER to 
weakly activate the UPR. In effect, BHPI distorts this normal action of E2-ER to kill 
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most ER+ cancer cells. Since E2-ER does not appear to activate the UPR in normal 
mammary cells, BHPI selectively targets the cancer cells and not normal ER+ cells. 
While UPR activation is normally transient, due to its mechanism of UPR activation, 
BHPI rapidly depletes intracellular ATP stores, activating the metabolic energy sensor, 
AMPK, and establishes a second site of protein synthesis inhibition that prevents the 
production of proteins required to shut off the UPR. This results in sustained UPR 
activation, inhibition of protein synthesis, and ultimately cell death. 
BHPI also restores sensitivity of multidrug-resistant ovarian cancer cells to 
therapeutically relevant concentrations of paclitaxel. Taxanes, are among the most 
commonly used cytotoxic drugs used in breast and ovarian cancer chemotherapy (15, 
16). Taxanes promote microtubule assembly and inhibit tubulin disassembly, which 
promotes apoptosis of cancer cells (17-19). While most epithelial ovarian cancer initially 
respond to taxanes, most advanced-stage cancers become resistant (20, 21). 
Overexpression of membrane efflux pumps, such as P-glycoprotein (MDR1/ABCB1), is 
the primary mechanism for paclitaxel resistance (22-25). We tested if BHPI could 
restore paclitaxel sensitivity to multidrug-resistant ER+ OVCAR-3 ovarian cancer cells, 
which overexpress MDR1/P-glycoprotein (26, 27). Treating cells with therapeutically 
relevant concentrations of paclitaxel (100 nM-10 μM) (28), did not kill OVCAR-3 cells. 
However, treating cells with 1 μM BHPI and 10 nM paclitaxel led to a >80% reduction in 
cell number. A future direction of this work will involve trying to decipher how BHPI 
restores taxane sensitivity in multi-drug resistant cells, and to assess whether targeting 
this pathway can serve as a viable avenue for targeting multi-drug resistant cancer 
cells. 
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BHPI offers the potential to significantly increase the reach of endocrine 
therapies for breast and gynecologic cancer. Previously reported non-competitive ER 
inhibitors have usually not advanced through preclinical development. The inhibitors 
DIBA, TPBM, TPSF, and newly described LRH-1 inhibitors that reduce ER levels, 
show limited ER+ specificity, require >5 M to inhibit cell proliferation and effectiveness 
has not been demonstrated in therapy resistant ER+ ovarian cancer cells (29-31). In 
contrast, BHPI is far more potent and specific, is effective in breast and ovarian cancer 
cells resistant to antiestrogens and chemotherapy, and at a modest dose of 15 
mg/kg/day induced rapid and substantial tumor regression. Our finding that BHPI is 
effective in a broad range of ER containing breast, ovarian and endometrial cancer 
cells is consistent with recent findings demonstrating these cancers exhibit common 
genetic alterations, and suggesting they might respond to the same drugs (32). 
Using BHPI as a small molecule probe, we identified a novel pathway of ER 
action that appears to be ubiquitously activated by estrogens in ER cancer cells. Our 
findings that estrogen activates the UPR (33), along with a recent study showing that 
VEGF also weakly activates the UPR (34), together propose a completely new mode of 
UPR activation in cancer. Prior to these studies, little was known about the potential role 
in cancer of a different mode of UPR activation involving anticipatory activation of the 
UPR prior to accumulation of unfolded protein or cell stress. This work has shown that 
estrogen, acting via estrogen receptor  (ER), induces rapid anticipatory activation of 
the UPR, resulting in increased production of antiapoptotic chaperones, which prepares 
cancer cells for the increased protein production required for subsequent estrogen-ER 
induced cell proliferation. In ER containing cancer cells, estrogen activates the UPR 
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through a phospholipase C  (PLC)-mediated opening of EnR IP3R calcium channels, 
enabling passage of calcium from the lumen of the EnR into the cytosol. Estrogen-ER 
activates all three arms of the UPR in breast and ovarian cancer cells in cell culture and 
in a mouse xenograft. In addition, these studies have shown that mild and transient UPR 
activation by estrogen promotes an adaptive UPR response that protects cancer cells 
from undergoing apoptosis when subsequently exposed to otherwise lethal levels of 
stress. This finding suggest that the biological relevance of estrogen-dependent activation 
of the UPR lies in its ability to protect cancer cells from subsequent exposure to 
environmental stresses that include hypoxia, drug therapy, and radiation.  
This mechanism of estrogen action via anticipatory activation of the UPR is a new 
paradigm by which estrogens may influence tumor growth, progression and resistance to 
therapy. The UPR index we identified is an exceptionally robust prognostic marker. For 
example, in a cohort of 474 ER+ breast cancer patients treated 5 years with tamoxifen 
and followed for 15 years, ~70% of patients with a low UPR index at diagnosis, 
experienced relapse-free survival, while fewer than 10% of those with a high UPR gene 
index experienced relapse-free survival (HR=3.7 Log Rank P <0.01). Importantly, the 
UPR index exhibits predictive power in multivariate analysis over and above current 
clinical covariates, such as tumor size and node involvement. Future work will address 
whether this UPR gene signature has the potential to serve as a diagnostic marker. Future 
studies will be geared toward trying to visualize UPR activation in mouse xenograft 
tumors, and whether UPR activation can be used to monitor tumor metastases to distant 
sites. The idea that prior activation of the cancer cell’s stress response pathway is a 
prognostic marker predicting aggressive, metastatic, therapy-resistant breast cancers is 
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a novel concept and potentially could represent a new prognostic biomarker, diagnostic 
marker and therapeutic target. 
Future work also aims to address whether anticipatory activation of the UPR 
extends beyond estrogen to other cancer mitogens. Recent work suggests that the 
mitogen, epidermal growth factor (EGF), acting through EGFR, also weakly activates 
the UPR through a PLCγ-dependent mechanism. It is well established that EGFR is 
overexpressed in a number of human malignancies including lung, pancreatic, brain, 
bladder, and breast cancer. EGF receptors are expressed in most breast cancers, but 
are overexpressed in 50% of triple-negative (ER-, PR-, and HER2/neu-) breast cancers 
and frequently overexpressed in highly-aggressive invasive breast cancer (IBC) (35-37). 
Furthermore, EGFR overexpression is associated with larger tumor size, poor 
differentiation, and poor clinical outcome (38-40). Our present data suggests that EGF 
may also similarly drive expression of the UPR, which ultimately makes cells more 
resistance to conventional therapies in cancer treatment.  
Our surprising finding that UPR activation is important for subsequent E2-ER 
regulation of gene expression is supported by a very recent report that activation of the 
UPR using a regulated system for production of unfolded protein enhances E2-ER 
induced gene expression (41). Very rapid anticipatory activation of the UPR is essential 
for subsequent E2-ER induced cell proliferation. Several very recent reports suggest 
this newly described role for the UPR is conserved across species and classes of 
mitogens. The insect steroid hormone ecdysone elicits anticipatory activation of the 
UPR. This ecdysone-ecdysone receptor-mediated activation of the UPR is required for 
ecdysone to stimulate metamorphosis and cell proliferation (42). Moreover, the peptide 
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hormone mitogens VEGF elicit anticipatory activation of the UPR as part of its pathway 
of action (34). Since several other mitogens, including fibroblast growth factor (FGF), 
phosphorylate and activate PLC, it is probable that they also elicit anticipatory 
activation of the UPR through this pathway (p-PLC IP3 IP3:IP3R intracellular 
Ca2+). Thus, anticipatory activation of the UPR appears to be a new type of cell 
proliferation checkpoint. If cells cannot activate the UPR to ready themselves for 
proliferation, they do not proceed through the cell proliferation program.  
Activation of the UPR that anticipates future stress is both a new pathway for 
activation of the unfolded protein response and a new role for the UPR. Previously, the 
UPR was known to be activated by sensors that sense unfolded protein and other 
stressors and respond by triggering UPR activation. This is sometimes termed the 
“reactive” mode for UPR activation. The PLC mediated pathway for UPR activation we 
identified describes a new “anticipatory” mode of UPR activation that readies cells for 
subsequent stress they will encounter as they proliferate. 
Classically, a new pathway related to cancer is identified and proposed as a 
potential drug target, and in subsequent studies a lead small molecule inhibitor might be 
identified. We turn this approach 180 and start with unbiased screening to generate a 
large data set from which we choose a lead small molecule inhibitor whose properties in 
simple follow on assays suggest it is likely to exhibit an unexplored mode of action.  
Then we progress from identification of the inhibitors mode of action to the relation of 
that action to previously undescribed normal actions of its target. For a well-studied 
protein, such as ER, it was unclear whether this approach could identify new pathways 
and biomarkers and promising new drug candidates. These studies demonstrate the 
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potential of small molecules identified from a large database generated by targeted cell-
based high throughput screening, to reveal and validate new pathways of action, 
therapeutic drug targets, and small molecule therapeutic candidates; even in a system 
as intensively studied as ER positive breast and ovarian cancer. 
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